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During the perinatal time period, the mammalian brain is developing rapidly and is 92 
particularly sensitive to inflammation.  Inflammation during this time period may be linked to 93 
later neurological illness in humans.  Disease-associated alterations in learning and behavior 94 
can be modeled in rodents using perinatal immune stimulation with either infectious agents or 95 
Toll-like receptor (TLR) agonists.  Although the gestational period is a particularly sensitive time 96 
for neurodevelopment, it is not known for how long after birth this sensitivity persists.  In mice, 97 
susceptibility to neurological infection declines dramatically during the first weeks of life.  98 
Therefore, we sought to compare the neuroinflammatory responses of neonatal and weanling 99 
mice.  To do so, we injected neonatal and weanling mice intracerebrally (IC) with 100 
lipopolysaccharide (LPS) or CpG oligodinucleotides (CpG), ligands of TLRs 4 and 9, respectively.  101 
We compared the production of inflammatory mediators and immune cell activation in the 102 
brain at each age.  Despite lower Tlr mRNA expression in neonatal brains, TLR4 and TLR9 103 
stimulation induced substantially higher levels of some cytokines in neonatal brains.  We also 104 
detected age-associated differences in expression of a subset of microglial activating and 105 
inhibitory receptors, as well as age-associated differences in the immune populations present in 106 
the brain.  We specifically examined whether the prion protein, PrPc, plays an 107 
immunomodulatory role in the brain.  PrPc expression influences immune cell activation in the 108 
periphery, increases in the brain with age, and influences several aspects of glial cell function.  109 
Since glia are the primary immune-responsive cells in the brain, we hypothesized that PrPc 110 
would influence the neuroinflammatory response.  However, we found no PrPc–dependent 111 
differences in cytokine production or glial activation in vivo in neonatal or weanling mice.  112 
Collectively, our data demonstrate that the neuroinflammatory response to TLR stimulation is 113 
developmentally regulated in young mice, although independent of PrPc expression. 114 
 115 
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CHAPTER ONE 266 
INTRODUCTION 267 
Cells of the central nervous system 268 
 Neurons, astrocytes and oligodendrocytes in the central nervous system (CNS) arise 269 
from a common neuroepithelial progenitor cell.  In contrast, microglia, the other prominent 270 
CNS cell type, are of myeloid origin.  In humans, neurons constitute about half of the brain’s 271 
cells (Azevedo et al., 2009; Lent et al., 2012).  Glial cells—oligodendrocytes, astrocytes, and 272 
microglia largely account for the rest of the brain’s cells, with a small percentage being 273 
epithelial and endothelial cells.  In the human cortex, which is responsible for higher brain 274 
function, approximately 75% of glial cells are oligodendrocytes, about 20% are astrocytes and 275 
5% are microglia (Pelvig et al., 2008).  Despite accounting for a relatively small percentage of 276 
the brain’s cells, astrocytes and microglia perform critical roles during development, disease 277 
and maintenance of homeostatic conditions.  The percentage of each cell type in the rodent 278 
brain is not as well studied. 279 
Neurons are highly specialized cells that transmit and accept electrical impulses and 280 
neurotransmitters.  Neurotransmission occurs at specialized cellular junctions called synapses.  281 
Most neurons are terminally differentiated and generation of new neurons from 282 
neuroprogenitor cells is limited in adults.  In contrast with most tissues, which undergo regular 283 
cellular turnover, neurons exist for the lifetime of the animal.  Thus, one of the main functions 284 
of microglia and astrocytes is to protect neurons and aid their recovery from damage and 285 
disease.   286 
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Oligodendrocytes produce myelin, which sheaths neuronal axons, allowing rapid 287 
transmittance of impulses from one neuron to another.  In the peripheral nervous system, this 288 
role is filled by Schwann cells.  Myelination is absolutely essential for proper nervous system 289 
function in vertebrates. 290 
Astrocytic processes envelope neurological synapses and rapidly take up excess 291 
neurotransmitters after neurotransmission (Danbolt, 2001).  Prolonged exposure of neurons to 292 
neurotransmitters quickly leads to neurotoxicity (Rosenberg and Aizenman, 1989).  Astrocytes 293 
also promote neuronal health by producing neurotrophic factors (Airaksinen and Saarma, 2002; 294 
Petrova et al., 2003; Rudge et al., 1995).  Astrocytes are a critical part of the blood-brain-barrier 295 
(BBB) (Pekny et al., 1998; Wolburg and Lippoldt, 2002).  Astrocytic endfeet are the primary 296 
component of the glia limitans, which separates the perivascular space from the brain 297 
parenchyma, or tissue proper (Bechmann et al., 2007).  Although not considered an immune 298 
cell, astrocytes can produce inflammatory mediators, including cytokines and chemokines, in 299 
response to infection and damage (Bolin et al., 2005; Butchi et al., 2008; Butchi et al., 2010).   300 
Microglia are the primary immune sentinels of the CNS.  In addition to responding to 301 
pathogens and promoting inflammation, microglia clear cellular debris, and release trophic and 302 
anti-inflammatory factors that resolve the inflammatory response (Bessis et al., 2007; Prinz et 303 
al., 2011; Saijo and Glass, 2011).  Microglia are involved in CNS development.  They promote 304 
neurogenesis and synaptogenesis (Roumier et al., 2004; Sierra et al., 2010).  Microglia also 305 
regulate synaptic pruning and programmed cell death of excess neurons (Frade and Barde, 306 
1998; Paolicelli et al., 2011; Stevens et al., 2007; Wakselman et al., 2008).  307 
 308 
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The neonatal immune system 309 
In some respects, the neonatal immune response is immature when compared with its 310 
adult counterpart.  For example, immunological memory is not yet developed. However, in 311 
many ways the neonatal immune system is not immature as much as it is responding to the 312 
unique demands of its environment.  At birth neonates are moving from a sterile intrauterine 313 
environment to one in which microbes, both pathogenic and commensal, are ubiquitous (Levy, 314 
2007).  The skin and gut, being subject to immediate colonization after birth, display a distinct 315 
immune response that balances the risk of infection with the danger of responding too strongly 316 
to commensal microbes (Dorschner et al., 2003; Lotz et al., 2006; Tollin et al., 2005).  In the 317 
blood of neonates, some acute phase proteins are heightened in response to the mild hypoxia 318 
that results from normal labor and delivery (Jokic et al., 2000; Levy et al., 2006a).  As a final 319 
example of the unique demands placed on the neonatal immune system, many inflammatory 320 
proteins have additional functions in neurological development.  Complement proteins mediate 321 
neurogenesis and migration of neuroprogenitors to their proper location (Rutkowski et al., 322 
2010).  The cytokine IL-6 promotes neurite growth in vitro.  Many immune molecules and cells 323 
are developmentally regulated during the period surrounding birth.  In many tissues, neonatal 324 
immune stimulation can have consequences that differ from other ages (Chelvarajan et al., 325 
2007; Ferret-Bernard et al.; Lotz et al., 2006).        326 
 327 
Origins of CNS myeloid cell populations 328 
Macrophages are highly heterogeneous cells that reside in every tissue in the body, 329 
their precise functions and capabilities dictated by the tissue they inhabit (Murray and Wynn, 330 
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2011).  Tissue-specific macrophages derive from multiple origins (Schulz et al., 2012).  Early in 331 
fetal development, a portion of the tissue-specific macrophage populations arise from extra-332 
embryonic yolk sac macrophages (Ginhoux et al., 2010; Schulz et al., 2012).  Later in 333 
development, hematopoietic stem cells (HSCs) give rise to myeloid progenitors (MPs).  MPs can 334 
differentiate into monocytes and tissue macrophages.  Monocytes circulating in the blood may 335 
also enter tissues and differentiate into macrophages (Auffray et al., 2007).  Thus, tissue-336 
specific macrophages may originate from yolk sac macrophages, HSCs, and blood monocytes.   337 
In the CNS, cells of myeloid origin include microglia and macrophages.  CNS 338 
macrophages reside within the perivasculature, meninges and choroid plexus.  Resident 339 
macrophages derive from, and are regularly replenished by, blood monocytes (Bechmann et al., 340 
2001; Chinnery et al., 2010).  Microglia are the only CNS myeloid cells that reside beyond the 341 
blood brain barrier (BBB) in the brain parenchyma.  Microglia probably differentiate from yolk 342 
sac macrophages and HSCs, although the precise contribution of each precursor to the 343 
microglial population is currently a matter of debate (Ginhoux et al., 2010; Samokhvalov et al., 344 
2007; Schulz et al., 2012).  In mice, the microglial population increases sixteen-fold during the 345 
first two post-natal weeks (Alliot et al., 1999).   These new microglia derive from dividing 346 
resident microglia (Ginhoux et al., 2010).  Microglia are one of the few tissue macrophage 347 
populations replenished through self-renewal and not blood-derived monocytes.   348 
 349 
CNS myeloid cell functionality 350 
Research has demonstrated important functional differences between the populations 351 
of CNS myeloid cells (El Khoury et al., 2007; Mildner et al., 2011; Simard et al., 2006).  352 
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Parenchymal microglia differ from resident macrophages in several ways.  In addition to 353 
deriving, at least partially, from a different progenitor cell and being replenished by self-354 
renewal, microglia express different patterns of cell surface markers than other CNS myeloid 355 
cells (Ransohoff and Cardona, 2010).  Immune cell markers are frequently expressed at lower 356 
levels on microglia.  For example, microglia express little MHC class II, which is in line with their 357 
reduced ability to present antigen.  In contrast, resident macrophages are able to present 358 
antigens to T cells that have been previously activated in peripheral tissues (Hickey and Kimura, 359 
1988).  Unlike other myeloid cells, microglia express ion channels, neurotransmitter receptors, 360 
and a greater range of purinoceptors (Färber and Kettenmann, 2005; Färber and Kettenmann, 361 
2006; Hanisch and Kettenmann, 2007).   362 
Blood monocytes may be stimulated to enter the brain parenchyma under experimental 363 
conditions (Mildner et al., 2007; Simard et al., 2006).  When this occurs they can differentiate 364 
into microglia-like cells.  However, they have different functional capabilities than microglia.  365 
For example, blood monocytes are better able to phagocytize Aβ fibrils (El Khoury et al., 2007).  366 
Whether blood monocytes are able to enter the brain parenchyma in human neurological 367 
conditions is unclear. 368 
Neonatal microglia are thought to exist in an elevated activation state due to their 369 
developmental roles in this time period (Bilbo and Schwarz, 2009).  Whether neonatal CNS 370 
macrophages also have specific developmental roles that would influence their activation state 371 
in neonates is unknown.  Thus, microglia, as well as resident macrophages, may contribute to 372 
age-dependent differences in responses to immune stimulation.  It is also unclear whether age-373 
associated differences in recruitment of blood monocytes occur after TLR stimulation (Levy, 374 
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2007).  While neonatal monocytes are known to respond differently than adult monocytes in 375 
peripheral responses to immune stimulation, they may also behave differently than resident 376 
microglia (Kollmann et al., 2009; Nguyen et al., 2010).   377 
 378 
Surveillant and activated microglia 379 
Under normal conditions, microglia are often described as “resting” or “quiescent”.  380 
These descriptions, which imply a degree of dormancy, are based on physical appearance and 381 
do not give an accurate indication of the cells’ activity level.  It is more accurate to refer to 382 
resting microglia as surveillant because they are active, but not in the proinflammatory way 383 
that is traditionally meant when microglia are described as active (Prinz et al., 2011).  384 
Surveillant microglia have a ramified phenotype, with many fine processes that are highly 385 
motile, constantly surveying their local environment for signs of disease or damage 386 
(Nimmerjahn et al., 2005). Their physical appearance is very different from “activated” 387 
microglia, which have retracted their processes and taken on an amoeboid appearance that is 388 
more similar to a typical macrophage.  Amoeboid microglia have generally been activated by 389 
inflammation, produce large amounts of inflammatory molecules, and are highly phagocytic 390 
(Saijo and Glass, 2011).  The switch from surveillant to amoeboid is not an all or nothing 391 
phenomenon.  Activated microglial phenotypes often exist as gradations between ramified and 392 
amoeboid (Graeber, 2010).  Complete retraction of processes into a fully amoeboid morphology 393 
is rare.  Healthy microglia return to a ramified phenotype once the situation requiring their 394 
activation is resolved.  Neonatal microglia have an amoeboid morphology, which is correlated 395 
with increased phagocytic ability (Fig 1.1).  In contrast, weanling microglia have a ramified 396 
~ 7 ~ 
 
phenotype with many fine processes.  When microglia become over-activated by excessive 397 
inflammatory stimulation, they may be unable to transition to a surveillant state and instead 398 
chronically produce pro-inflammatory mediators, leading to significant tissue damage over 399 
time.  This may occur in immune-stimulated neonatal microglia (Bilbo and Schwarz, 2009).  400 
Chronically over-activated microglia are not amoeboid but instead have several extremely thick 401 
processes (Bilbo and Schwarz, 2009).  Additionally, acute encephalitic conditions can lead to 402 
activated microglia possessing a long and slender rod cell phenotype (Ackman et al., 2006; 403 
Graeber, 2010).   404 
 405 
Toll-like receptors  406 
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs), a large and diverse 407 
family of proteins united in their ability to recognize pathogen-associated molecular patterns 408 
(PAMPs).  PRR binding is often the first step in immune recognition and response to an invading 409 
pathogen. TLR stimulation activates production of cytokines and anti-microbial effector 410 
molecules (West et al., 2006).  TLRs are prominently expressed on immune cells such as 411 
monocytes, macrophages and DCs (West et al., 2006).  In the central nervous system (CNS), 412 
they are expressed on astrocytes and microglia and, to a lesser extent, neurons (McKimmie and 413 
Fazakerley, 2005).  TLRs localize to either the plasma membrane or endosomal membranes 414 
(Barton and Kagan, 2009; Kagan et al., 2008).  Plasma membrane-associated TLRs, such as TLR4, 415 
recognize components of bacterial outer membranes and viral envelopes.  Endosomal TLRs, 416 
such as TLR9, recognize microbial nucleic acids.  We have focused on TLR4 and TLR9 stimulation 417 
with their ligands, lipopolysaccharide (LPS) and CpG-rich oligonucleotides (CpG), respectively.  418 
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We chose TLRs 4 and 9 due to their potential to interact with the prion protein.  This will be 419 
discussed further in chapter three. 420 
 421 
TLR signaling 422 
TLR4 signaling is often used as a model for TLR signaling because it is well-studied and 423 
TLR4 signals from both the plasma membrane and endosome (Fig 1.2).  TLR4 stimulation leads 424 
to the production of pro-inflammatory cytokines through activation of several intracellular 425 
signaling pathways (Barton and Kagan, 2009; Ostuni et al., 2010).  Upon ligand binding at the 426 
plasma membrane, TLR4 signaling leads to an initial activation of the transcription factors NFκB 427 
and AP-1.  The TLR4 complex is then endocytosed.  From the endosome, TLR4 stimulates a 428 
second round of NFκB and AP-1 activation, as well as activation of the transcription factor IRF3.  429 
The first round of NFκB and AP-1 activation is mediated by the adaptor MyD88.  The second 430 
round of TLR4-mediated transcription factor activation is mediated by TRIF rather than MyD88.  431 
NFκB and AP-1 activation leads to the production of pro-inflammatory cytokines, with the 432 
exception of the type I interferons, which are induced by IRF3.    433 
TLR signaling is complex; the precise outcomes of ligand binding are influenced by 434 
numerous intracellular adaptor proteins, which are modulated by the host cell’s differentiation 435 
and activation state.  Two features that guide TLR signaling are membrane phospholipid 436 
composition and polyubiquitin scaffolds.  Membrane phospholipids control the cellular location 437 
of the TLR4 complex and provide binding sites for necessary intracellular adaptors (Kagan and 438 
Medzhitov, 2006; Triantafilou et al., 2004).  Polyubiquitin scaffolds provide docking sites for 439 
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intracellular proteins critical to the activation of downstream transcription factors (Deng et al., 440 
2000; Fan et al., 2010). 441 
Recognition of LPS by TLR4 is aided by several accessory proteins.  The secreted LPS 442 
binding protein (LBP) sequesters LPS monomers and presents them to CD14, which has an 443 
extremely high affinity for LPS (Gioannini et al., 2004; Wright et al., 1990).  At the plasma 444 
membrane, CD14 transfers LPS to the TLR4:MD-2 complex (Gioannini et al., 2004).  Concurrent 445 
with TLR4:MD-2 stimulation, CD14 interacts with CD11b (CR3) (Zarewych et al., 1996).  CD11b 446 
may promote synthesis of the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) by 447 
the kinase PI(4)P5K (Hynes, 2002; Ostuni et al., 2010).  In response to TLR4 ligand binding, both 448 
PIP2 and TLR4 are concentrated in lipid rafts.  TLR4 is not normally found in lipid rafts but must 449 
be recruited and retained there for effective TLR signaling (Triantafilou et al., 2004).   450 
On the cytosolic side of the plasma membrane, the sorting adaptor TIRAP is recruited by 451 
the relatively high concentrations of PIP2 (Kagan and Medzhitov, 2006).  TIRAP engages the 452 
signaling adaptor MyD88, which interacts sequentially with the IRAK effector proteins, leading 453 
to recruitment of the E3 ubiquitin ligase TRAF6 (Cao et al., 1996; Kagan and Medzhitov, 2006; 454 
Kawagoe et al., 2008; Suzuki et al., 2002).  TRAF6 self polyubiquitination serves as a docking 455 
point for the IKK regulatory complex and the kinase TAK1 (Deng et al., 2000; Fan et al., 2010).  456 
Activated IKK promotes NFκB activation by phosphorylating IκB, leading to its degradation.  457 
NFκB, which is normally sequestered in the cytosol by IκB, is now able to translocate into the 458 
nucleus and induce pro-inflammatory gene expression (Doyle and O'Neill, 2006; Li and Stark, 459 
2002).  During inflammatory signaling, AP-1 activation is primarily regulated by the nuclear MAP 460 
kinases (MAPKs) p38, JNK, and ERK (Ostuni et al., 2010).  Nuclear MAPK activation is connected 461 
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to the TLR signaling pathway by TAK1.  As an activator of both IKK and the MAPKs p38 and JNK, 462 
TAK1 is the branching point at which AP-1 activation diverges from NFκB activation in the 463 
MyD88-dependent pathway (Sato et al., 2005; Wang et al., 2001).   464 
The above events described for MyD88-dependent signaling from the plasma 465 
membrane occur within 15-30 minutes of stimulation (Husebye et al., 2006; Kagan et al., 2008).  466 
After this, the concentration of PIP2 in the plasma membrane declines significantly, leading to 467 
endocytosis of the TLR4 signaling complex (Botelho et al., 2000; Ostuni et al., 2010).  Decreased 468 
PIP2 also results in TIRAP dissociating from the complex.  With TIRAP gone, another sorting 469 
adaptor, TRAM, is able to bind the intracellular domain of TLR4 (Yamamoto et al., 2003).  TRAM 470 
recruits the signaling adaptor TRIF, which engages the kinase RIP-1 (Meylan et al., 2004).  From 471 
this point on, the events leading to late NFκB signaling are similar to those described for early 472 
NFκB signaling.   473 
To activate IRF3, the signaling adaptor TRIF interacts with TRAF3, whose self-474 
ubiquitination leads to IRF3 activation (Hacker et al., 2006).  Under basal conditions, IRF3 is a 475 
cytosolic monomer but activating phosphorylation triggers dimerization and nuclear 476 
translocation, permitting induction of the type I interferons, IFN-α and IFN-β (Honda et al., 477 
2006).   478 
TLR4 signaling ends when the endosome matures.  At this time the TRAM splice variant, 479 
TAG, displaces TRIF in binding to TRAM, leading to endolysosomal degradation of TLR4 480 
(Husebye et al., 2006; Palsson-McDermott et al., 2009).   481 
TLR9 recognizes bacterial and viral unmethylated CpG DNA.  In unstimulated cells, TLR9 482 
is found in the endoplasmic reticulum (ER) (Latz et al., 2004; Leifer et al., 2004).  In response to 483 
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immune stimulation, the sorting protein UNC93B1 transports inactive TLR9 from the ER to the 484 
endolysosomal pathway (Kim et al., 2008; Tabeta et al., 2006).  Upon entering the 485 
endolysosome, TLR9 is proteolytically cleaved (Ewald et al., 2008; Park et al., 2008).  Notably, 486 
full-length TLR9 can bind CpG DNA but cannot bind the intracellular signaling adaptor protein 487 
MYD88 (Barton and Kagan, 2009; Ewald et al., 2008).  Therefore, proteolytic cleavage regulates 488 
the ability of TLR9 to transmit immune stimulatory signaling.  Upon ligand binding and 489 
proteolytic cleavage, TLR9 binds MYD88, which leads to downstream signaling similar to what 490 
was previously described for endosomal TLR4 signaling (Fig 1.3) (Barton and Kagan, 2009; West 491 
et al., 2006).  TLR9 signaling culminates in induction of cytokine genes, including the 492 
interferons, and other inflammatory mediators. 493 
 494 
TLR signaling in development 495 
Tlr4 and Tlr9 mRNA expression are developmentally regulated in the murine brain.  In 496 
mice, brain Tlr9 expression increased from embryonic time points through adulthood (Kaul et 497 
al., 2012).  In rats, brain Tlr4 mRNA expression increased from birth through adulthood (Ortega 498 
et al., 2011).  However, TLR4 protein levels in the rat brain remained stable over the same time 499 
period (Ortega et al., 2011).  Among peripheral immune populations, Tlr9 mRNA expression 500 
levels in human adult and cord blood monocytes were similar (Dasari et al., 2011), as were TLR9 501 
protein levels on human plasmacytoid dendritic cells from adult peripheral blood and cord 502 
blood (Danis et al., 2008).  Two human studies found no difference in monocytic Tlr4 expression 503 
between neonates and adults (Dasari et al., 2011; Levy et al., 2004).  However, in young mice 504 
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(9-12 days old), macrophage TLR4 expression was decreased when compared with expression 505 
in adult macrophages (Chelvarajan et al., 2004).   506 
A comprehensive analysis of TLR signaling pathway function in neonatal cells is 507 
complicated by the fact that studies are often done in different species, using different cell 508 
types and methods of harvesting cells, and different TLR ligands.  Despite this, some general 509 
patterns are emerging:  Cord blood monocytes have reduced MyD88 expression, p38 510 
phosphorylation, and IRF3 activation when TLR stimulation leads to reduced cytokine output 511 
(Aksoy, 2006; Levy et al., 2004; Sadeghi et al., 2007; Yan et al., 2004).  Enhanced cytokine 512 
production by cord blood monocytes is associated with increased p38 phosphorylation and IκB 513 
degradation (Levy et al., 2006b).   514 
 515 
The neonatal TLR response is stimulus- and cell type-specific 516 
Several cytokines, including IL-6 and IL-10, are elevated in neonates in numerous 517 
conditions and cell types outside the CNS (Angelone et al., 2006; Chelvarajan et al., 2004; 518 
Nguyen et al., 2010).  In contrast, other cytokines, such as IL-1b, IL-12, TNF and the interferons, 519 
are often expressed at reduced levels in neonatal immune cells that are isolated from 520 
peripheral blood and tissues and stimulated with TLR agonists (Belderbos et al., 2009; 521 
Chelvarajan et al., 2004; Islam et al., 2012b; Marodi, 2006).  However, research is increasingly 522 
showing that the neonatal cytokine response to TLR stimulation differs depending on the tissue 523 
and cell type stimulated, as well as the TLR ligand.  For example, in whole human blood 524 
stimulated with LPS, production of IL-6, IL-8 and IL-10 was heightened in neonates when 525 
compared with adult blood (Nguyen et al., 2010).  In comparison, when the TLR9 ligand CpG 526 
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was used, in addition to IL-6, IL-8 and IL-10, IL-1β was also elevated (Nguyen et al., 2010).  In 527 
sheep mesenteric lymph nodes, stimulation of TLR8 was able to potently overcome inhibition of 528 
Th1-promoting responses to produce higher amounts of IL-12 and IFNγ in neonates than adults 529 
(Ferret-Bernard et al.).  Stimulation with bacterial pathogens also leads to age-dependent 530 
cytokine responses in peripheral neonatal immune populations (Chelvarajan et al., 2007; Levy 531 
et al., 2006a). 532 
 533 
Prion protein and transmissible spongiform encephalopathies (TSEs) 534 
TSEs are a group of fatal neurodegenerative diseases that includes diseases of 535 
infectious, genetic, sporadic and iatrogenic origin (Caughey et al., 2009).  TSE pathology and 536 
transmissibility requires expression of the endogenous prion protein (Bueler et al., 1993).  In 537 
TSEs, the prion protein misfolds from its endogenous and non-pathogenic form, PrPc, into a 538 
pathogenic form, PrPSc, whose name derives from the prototypical TSE, ovine scrapie.  539 
Conformationally, PrPc has higher α-helical content while PrPSc contains reduced α-helix and 540 
increased levels of β-sheets.  Although TSE disease progression has been closely studied, the 541 
underlying pathological causes remain unclear.  Since misfolding of PrPc into PrPSc may lead to 542 
subversion of normal function, knowledge of the normal function(s) of PrPc may enlighten our 543 
understanding of TSE pathology. 544 
PrPc is a 254 amino acid protein that is glycosylated and primarily bound to the plasma 545 
membrane through a glycophosphatidyl inositol (GPI) anchor.  Despite PrPc’s apparent 546 
involvement in an array of physiological processes, its precise function remains poorly defined 547 
(Linden et al., 2008).  Some proposed functions, such as adhesion and differentiation, are 548 
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applicable to many cell types and may reflect the near ubiquitous distribution of PrPc.  Others, 549 
such as mitigating excitotoxicity and acting as a scavenger receptor (Khosravani et al., 2008; 550 
Marc et al., 2007; Sunyach et al., 2003), could reflect functions in specific cell types like neurons 551 
and microglia.  PrPc functions associated with immunity and development are discussed in 552 
chapter three. 553 
 554 
TLR signaling influences the TSE incubation period 555 
Mice deficient in TLR4 signaling have a shortened scrapie incubation period (Spinner et 556 
al., 2008).  Notably, MyD88 deficiency does not impact the scrapie incubation period (Prinz et 557 
al., 2003).  This implies the MyD88-independent, TRIF-dependent TLR signaling pathway may 558 
influence scrapie disease progression.  In agreement with this, a recently published paper 559 
demonstrates a shortened scrapie incubation period in mice lacking IRF3, a critical transcription 560 
factor in MyD88-independent signaling (Ishibashi et al., 2012).  IRF3 activates many immune-561 
responsive genes, including type I interferons.  However, stimulation with interferons does not 562 
influence the scrapie incubation period (Field et al., 1969; Gresser et al., 1983).  In addition, 563 
inoculation with the TLR9 ligand unmethylated CpG ODNs prolongs the scrapie incubation 564 
period (Sethi et al., 2002).  565 
 566 
Overview 567 
In mice, the neonatal brain is much more sensitive to infection than the weanling brain. 568 
Therefore, I hypothesized that the neuroinflammatory response would be altered in an age 569 
dependent manner in mice.  To model neuroinflammation, I injected neonatal and weanling 570 
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mice intracerebrally (IC) with either the TLR4 agonist LPS or the TLR9 agonist CpG ODN.  I aimed 571 
to compare expression of some neuroinflammatory mediators, including a subset of cytokines, 572 
at each age in order to gain insight into how the immune response changes with age.  I was 573 
particularly interested in examining the activation profiles of microglia, as they are important 574 
mediators of the inflammatory response in the brain and their activation may be influenced by 575 
age.  Therefore, for my second aim, I compared expression of activating and inhibitory markers 576 
on neonatal and weanling mice.  Lastly, I aimed to determine whether PrPc mediates 577 
neuroinflammation in an age-dependent manner, since PrPc expression increases with age and 578 
has previously been associated with various immunological functions. 579 
 580 
 581 
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 582 
Figure 1.1 Microglial morphology is influenced by age and previous immune challenge.  583 
Summary of how microglial phenotype changes with age and in response to immune challenge 584 
in murine models of development and disease.  Time line shown is for mouse development.  585 
Modified from Bilbo & Schwartz, Frontiers Behav. Neuro., 2009. 586 
 587 
 588 
 589 
 590 
 591 
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 592 
Figure 1.2 Activated TLR4 signals from the plasma membrane and the endosome.  Ligand 593 
binding stimulates recruitment of TLR4 into lipid rafts, where early TLR signaling is initiated.  594 
Upon endocytosis, TLR4 activates late TLR signaling from the endosome.  From Ostuni et. al., 595 
Cell. Mol. Life Sci., 2010. 596 
 597 
 598 
 599 
 600 
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 601 
Figure 1.3 Activated TLR9 signaling from the endosome.  Ligand binding and proteolytic 602 
cleavage lead to TLR9 signaling from the endolysosomal pathway.  From Kawai & Akira, Cell 603 
Death & Differentiation. 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
~ 19 ~ 
 
CHAPTER TWO 613 
SUPPORTING DATA FOR ANALYSIS OF  614 
AGE-ASSOCIATED CHANGES IN NEUROINFLAMMATORY RESPONSE 615 
Background studies on influence of age and agonist concentration on in vivo cytokine 616 
production  617 
In previous studies using the IRW mouse strain, a strong neuroinflammatory response 618 
was observed in neonatal mice after intracerebral (IC) inoculation with 1 µg LPS per gram of 619 
body weight (Butchi et al., 2008).  To determine the best concentration of LPS to use in 620 
neonatal C57Bl/10 mice for IC inoculations, we tested 0.25, 0.5 and 1 µg LPS per gram of body 621 
weight.  Cytokine protein levels in brain tissue were measured using a multiplex bead assay.  622 
Representative data are shown in Figure 2.1.  One microgram LPS per gram of body weight was 623 
fatal to nearly fifty percent of C57Bl/10 mice (Fig 2.1A).  We observed a similar mortality rate in 624 
C57Bl/10 PrP-/- mice (data not shown).  With the exception of IL-6 (p=0.0058), the cytokine 625 
response to 0.5 µg LPS per gram body weight did not differ significantly from the cytokine 626 
response to 1 µg LPS per gram of body weight (Fig 2.1B). However, at 0.5 µg LPS per gram body 627 
weight, all mice survived.   Therefore, we used 0.5 µg LPS per gram body weight in all future 628 
treatments.  We also halved the CpG concentration that had been used in IRW mice to 0.125 µg 629 
CpG (40 picomole) per gram of body weight, in case the C57Bl/10 mice were also more reactive 630 
to this TLR ligand.  631 
 To better understand how the cytokine response to TLR 4 and 9 stimulation develops 632 
with age, we also examined IL-6 and CCL2 production in 10 and 42 day old (d.o.) mice.  We 633 
chose the 10 d.o. age because susceptibility to Sindbis virus infection of the CNS decreases 634 
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dramatically by 11 days of age (Trgovcich et al., 1999).  Since 21 d.o. mice are not yet adult, we 635 
also examined how the weanling response differs from that of a 42 d.o. adult.   636 
 Figure 2.2 shows the IL-6 and CCL2 protein production in response to TLR4 or TLR9 637 
stimulation in 2, 10, 21 and 42 d.o. mice.  Although the 2 and 21 d.o. samples were analyzed 638 
separately from the 10 and 42 d.o. samples, standards were comparable between experiments.  639 
The IL-6 response to TLR4 stimulation consistently declined with age over the time course 640 
analyzed.  The CCL2 response to TLR4 stimulation showed an overall decline with age, although 641 
CCL2 levels were slightly higher in 21 d.o. mice than 10 d.o. mice.  CCL2 production in response 642 
to TLR9 stimulation dramatically decreased in mice beyond the neonatal time period and 643 
remained low.  In contrast, IL-6 production decreased from 2 to 21 days of age but sharply 644 
increased in 42 d.o. mice.  Collectively, these data suggest that production of IL-6 and CCL2 645 
depends not only on age, but also on the type of immune stimulant. 646 
 647 
Developing a flow cytometry protocol for analysis of LPS-stimulated CNS immune populations 648 
Many, if not all, cell types in the central nervous system can produce cytokines.  649 
However, we expected microglia and astrocytes to be important cytokine-producing cells in the 650 
brain during the response to TLR4 stimulation (discussed in Chapters 1 and 2). Initially, we 651 
planned to use flow cytometry to characterize and compare the activation states of neonatal 652 
and weanling microglia and astrocytes.  A major hurdle to flow cytometric analysis of brain cell 653 
populations ex vivo is myelin.  Contaminating myelin ovoids can be similar in size and shape to 654 
cells, making it impossible to gate them out based on size.  Myelin can also mask epitopes and 655 
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lead to non-specific antibody binding.  Myelination in the brain increases with age, so it is a 656 
bigger problem in weanlings than in neonates.   657 
To remove the myelin from our samples, we initially tried using Miltenyi myelin 658 
depletion columns.  With these columns, brain homogenates are pre-incubated with a myelin-659 
specific antibody and then placed on the myelin depletion columns.  Myelin should be retained 660 
on the column while cells are able to flow through.  We encountered obstacles to the effective 661 
use of these columns for preparing samples for flow cytometry.  First, the myelin removal 662 
columns did not satisfactorily remove non-myelin debris from the samples, which still allowed a 663 
high degree of non-specific antibody binding.  However, the most challenging problem we faced 664 
when using the myelin depletion columns was the apparent loss of certain cell types, including 665 
microglia, in LPS-stimulated flow cytometry samples (Fig 2.3).  This was observed in repeated 666 
experiments using mice of both ages. Representative samples pre-incubated with an antibody 667 
for CD11b are shown in Figure 2.3.  Similar results were observed using antibodies targeting 668 
CD45 and CD80 (data not shown).  The left graph shows the level of background fluorescence in 669 
an unstained control.  In the center graph, CD11b+ cells in PBS-treated samples are circled.  The 670 
right graph shows the reduced number of CD11b+ cells observed in LPS-treated samples. 671 
We then tried isolating CNS immune cells using Percoll gradients, and with additional 672 
trituration, instead of myelin depletion columns.  Percoll gradients are often used to isolate 673 
immune cells from other CNS components (Ford et al., 1995; Gelderblom et al., 2009; Mausberg 674 
et al., 2009; Peterson et al., 2006).  We did not initially use Percoll gradients because we 675 
planned to examine both microglial and astrocytic populations.  Using a 0/30/70% Percoll 676 
gradient, astrocytes primarily fractionate with myelin at the 0/30% interface [(Peterson et al., 677 
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2006) and Fig 2.4]. Therefore, these Percoll gradients are not a suitable method for isolating 678 
astrocytes for flow cytometric analysis.  As discussed in Chapter 2, the fraction at the 30/70% 679 
interface is enriched for microglia and other immune populations.   680 
Figure 2.5 shows samples prepared either using myelin depletion columns (left) or 681 
Percoll gradients (right).  Representative samples from neonatal (top) and weanling (bottom) 682 
uninoculated mice are shown.  The region where cells are expected to be is circled on the 683 
graphs (solid line).  Samples purified on myelin depletion columns contained more debris, as 684 
evidenced by the large number of events with high side scatter but little forward scatter.  We 685 
also noted fewer cells in weanling samples (bottom) than neonatal samples (top).   686 
Figure 2.6 compares CD45 and F4/80 staining on untreated cells isolated using either 687 
myelin depletion columns (A, C, E) or Percoll gradients (B, D, F).  Cell gates for these samples are 688 
shown in Figure 2.5.  Events within the cell gate of (A) myelin-depleted, or (B) Percoll gradient 689 
fractionated, neonatal samples are shown.  (C) and (D) show the same samples, except Aqua 690 
Live/Dead stain was used to gate specifically on live cells.  Comparing (A) with (C) demonstrates 691 
that gating specifically on live cells markedly reduced the noise in samples prepared using 692 
myelin depletion columns.  In contrast, comparing (B) with (D) shows that live cell gating does 693 
not greatly change the plots of samples prepared using Percoll gradients.  These results suggest 694 
that dead cells and debris are more effectively separated from CNS immune cells using Percoll 695 
gradients than myelin depletion columns.  Similar results were observed in weanling samples 696 
(data not shown).  A comparison of cells within the live cell gate of (E) myelin-depleted, or (F) 697 
Percoll gradient fractionated, weanling samples demonstrated that greater numbers of 698 
weanling microglia were isolated when samples were prepared using Percoll gradients.  699 
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Microglia are identified as CD45lo F4/80+.  Collectively, these results suggested that isolation 700 
and detection of microglia was improved by the use of Percoll gradients, rather than myelin 701 
depletion columns.  In further experiments, Percoll gradients were used to isolate CNS immune 702 
cells.   703 
While the use of Percoll gradients and trituration improved our isolation of microglia 704 
from untreated brain tissue, we still needed to improve recovery of LPS-stimulated CNS 705 
immune cells, particularly from weanling tissues.  To address this, we tried enzymatically 706 
digesting the tissue.  There are many published reports of successful preparation of CNS cells 707 
for flow cytometry using enzymatic digestion (Ford et al., 1995; Gelderblom et al., 2009; 708 
Gottfried-Blackmore et al., 2009; Mausberg et al., 2009).  We adapted the protocol of Cardona 709 
et al. because it was developed specifically for isolation of microglia for both flow cytometry 710 
and RNA analysis (Cardona et al., 2006), which we also planned to do.  In this protocol, 711 
homogenized brains are incubated with collagenase, dispase and DNase.  Collagenase and 712 
dispase cleave collagen and fibronectin, respectively, while DNase removes extracellular DNA 713 
from lysed cells.   714 
Figure 2.7 demonstrates that enzymatic digestion improved detection of LPS-stimulated 715 
CNS immune populations.  In this experiment, digested and undigested samples from neonatal 716 
and weanling mice, with or without LPS stimulation, were examined.  Enzymatic digestion did 717 
not markedly alter the detection of neonatal cell populations in untreated mice (A & E).  718 
However, in untreated weanling samples, digestion increased the number of microglia detected 719 
(C & G, solid line).  Surprisingly, without enzymatic digestion, loss of CD45hi cells was not 720 
observed in LPS-treated samples (B & D, arrows), as we observed previously (Fig 2.3).  The 721 
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results of the current experiment suggested that the modifications we previously made, namely 722 
the use of Percoll gradients and trituration, were sufficient to improve recovery of LPS-treated 723 
populations.  However, enzymatic digestion led to additional recovery of CD45hi cells in LPS-724 
treated samples (B & F, D & H, dashed line).  Therefore, enzymatic digestion was added to the 725 
protocol for future flow cytometry studies. 726 
 727 
Flow cytometry on ex vivo astrocytes  728 
Although CNS immune cell detection was greatly improved by the use of Percoll 729 
gradients, our standard Percoll gradients are not appropriate for recovery of astrocytes for flow 730 
cytometry (discussed previously).  Figure 2.8 demonstrates typical staining observed with an 731 
astrocyte-specific GFAP antibody.  The sample in this figure is from a PBS-inoculated neonatal 732 
mouse and was prepared using a myelin depletion column.  (A) shows staining of CD11b+ cells 733 
in this sample. (B) demonstrates GFAP+ staining.  (C) contains antibodies for both GFAP and 734 
CD11b.  Since GFAP and CD11b are found on separate populations, there should be no double-735 
positive staining in (C).  No distinct GFAP+ populations are apparent, as there are for CD11b.  736 
Thus, GFAP staining may have been non-specific.  Similar results were observed in weanling 737 
mice and in LPS-treated mice. 738 
Since isolation of CNS immune cells improved when we used a Percoll gradient instead 739 
of a myelin depletion column, we attempted to modify our standard Percoll gradient in order to 740 
separate astrocytes from myelin.  We tried a 0/15/70% gradient, hoping that myelin would stay 741 
at 0/15% interface and all cells would be at 15/70% interface.  Unfortunately, this did not work 742 
(data not shown).  We next tried a 0/20/30/70% Percoll gradient.  In this gradient myelin was 743 
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found at both the 0/20% and 20/30% interfaces (data not shown).  In summary, we were not 744 
able to find a satisfactory method to separate myelin and debris from GFAP+ astrocyte 745 
populations ex vivo.  Therefore, we limited our ex vivo flow cytometry analyses to CNS immune 746 
cell populations that could be effectively separated from debris through fractionation at the 747 
30/70% interface of Percoll gradients. 748 
 749 
Discussion 750 
 We were initially puzzled by the poor detection of CNS immune populations.  However, 751 
through a number of modifications to our protocol, we were able to substantially recover these 752 
populations.  The use of Percoll gradients and trituration led to recovery of microglia and a 753 
subset of CD45hi immune cells.  One reason these cells may have been so challenging to recover 754 
is that they are extremely sticky, particularly when activated.  They easily bind to one another 755 
or are lost during sample preparation through binding to the sides of tubes.  The difficulties we 756 
initially had may have been due to these cells being non-specifically retained on the myelin 757 
depletion columns, a problem that was circumvented by the use of Percoll gradients.  The 758 
additional trituration may have also assisted in the generation of detectable single cell 759 
suspensions. 760 
 Microglia are the largest immune population in the brain, so we were quite surprised 761 
when enzymatic digestion revealed large populations of CD45hi cells in LPS-treated tissues.  762 
Immune stimulation readily recruits peripheral immune populations into perivascular spaces 763 
within the blood brain barrier (BBB), although their ability to enter the brain parenchyma is 764 
much more limited (Bechmann et al., 2007; Ransohoff and Cardona, 2010).  Therefore, 765 
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enzymatic digestion may be required to sufficiently dissociate the BBB and recover cells within 766 
this space.  In support of this, Dick et al. demonstrated that dissection of the meninges, choroid 767 
plexus and ventricles away from the rest of the brain tissue reduced the number of CD45hi cells 768 
detected in the brain by five-fold (Dick et al., 1995). 769 
 In summary, we have optimized a protocol for the efficient isolation of CNS immune 770 
populations under both homeostatic and inflammatory conditions.  Unfortunately, we were 771 
unable to detect astrocytic populations without concomitant non-specific binding to myelin and 772 
other debris. 773 
 774 
 775 
 776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
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 788 
Figure 2.1 Determination of LPS dosage for intracerebral inoculation of neonatal mice.  789 
Newborn mice were inoculated IC with 0.25, 0.5 or 1 µg LPS per gram of body weight.  (A) The 790 
highest dosage was fatal for nearly half the mice.  n=8-9 per group.  (B) Cytokine responses in 791 
whole brain tissue were measured in a multiplex bead assay at 12 hpi.  Representative 792 
cytokines are shown here.  n=3-8 per group. 793 
 794 
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 801 
Figure 2.2 Cytokine responses differ with age and TLR agonist.  IL-6 and CCL2 levels were 802 
measured in 2, 10, 21 and 42 day old brain tissue after IC inoculation with LPS or CpG.  Protein 803 
concentrations were measured by ELISA and were calculated from in-plate standard curves 804 
generated with standards provided by manufacturer.  n = 4 mice per group.  Data are presented 805 
as mean +/- SD.  # indicates treatment group contains samples above the dynamic range (based 806 
on standard curve).  Statistical analysis was completed by two-way analysis of variance with 807 
Tukey’s multiple comparisons test.  Significant age-specific differences are as indicated: 808 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 809 
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 810 
Figure 2.3 LPS-stimulated cells isolated using myelin depletion columns are poorly detected 811 
by flow cytometry.  CD11b (AF700) staining is plotted against forward scatter for an unstained 812 
control, PBS- and LPS-treated neonatal samples.  Positive CD11b staining is circled in PBS- and 813 
LPS-treated samples.   814 
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 827 
Figure 2.4 Enrichment of astrocytic and microglial populations in separate Percoll gradient 828 
fractions.  Whole brain homogenates were layered over 0/30/70% Percoll gradients.  After 829 
centrifugation, mRNA expression in the cellular fractions at the 0/30% and the 30/70% 830 
interfaces was analyzed by qRT-PCR.  (A) Expression of the astrocytic marker Gfap is detected 831 
predominantly in the fraction at the 0/30% Percoll interface.  (B)  Expression of the microglial 832 
marker F4/80 is detected predominantly in the fraction at the 30/70% Percoll interface.  Data 833 
are presented as mean +/- SD.  n = 4-5 per group. 834 
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 843 
Figure 2.5 Comparison of cell populations isolated using myelin depletion columns or Percoll 844 
gradients.  Cell density plots of forward scatter versus side scatter are shown for neonatal (top) 845 
and weanling (bottom) samples.  Samples were prepared for flow cytometry either using myelin 846 
depletion columns (left) or Percoll gradients (right).  Only the 30/70% fraction of the Percoll 847 
gradient, which is enriched for CNS immune cells, is shown.  Cell population is outlined (not 848 
actual cell gate).   849 
 850 
 851 
 852 
 853 
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 854 
Figure 2.6 Comparison of CNS immune populations isolated using myelin depletion columns 855 
and Percoll gradients.  Different sample preparation methods were compared using untreated 856 
neonatal (A-D) and weanling (E-F) brain tissue.  Cell density plots of samples stained for the 857 
immune marker CD45 and the myeloid marker F4/80 are shown.  (A & B) show events within 858 
the cell gate, while samples in (C – F) have been gated on both for events within the cell gate 859 
and for live cells.  Cells were incubated with Aqua Live/Dead stain prior to fixation. 860 
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 861 
Figure 2.7 Enzymatic digest improves detection of LPS-stimulated CNS immune cells.  862 
Detection of CNS immune populations was compared after preparation of samples without (A – 863 
D) and with (E – H) enzymatic digestion (Collagenase D, Dispase I and DNase I) prior to Percoll 864 
gradient fractionation.  Cell density plots of samples stained for the immune marker CD45 and 865 
the myeloid marker F4/80 are shown.  Arrows indicate improved detection of LPS-stimulated 866 
immune populations, even in the absence of enzymatic digestion.  Dashed line circles show 867 
even greater detection of LPS-stimulated CD45hi populations after enzymatic digestion. 868 
 869 
 870 
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 872 
Figure 2.8 Flow cytometry of astrocytes ex vivo.  Staining for the myeloid cell marker CD11b 873 
and the astrocyte cell marker GFAP in a neonatal PBS-treated sample is shown.  These markers 874 
are not expected to exist on the same cell population in the brain, so double positive staining is 875 
not expected.  (A) Sample is stained with antibody for CD11b only.  (B) Sample is stained with 876 
antibody for GFAP only.  (C) Sample includes antibodies for both GFAP and CD11b. 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
 886 
 887 
~ 35 ~ 
 
CHAPTER THREE 888 
AGE-ASSOCIATED CHANGES IN THE ACUTE NEUROINFLAMMATORY RESPONSE  889 
TO TLR4 AND TLR9 STIMULATION IN YOUNG MICE 890 
Introduction     891 
During the perinatal period, the mammalian brain is developing rapidly and is 892 
particularly sensitive to inflammation.  Gestational viral, bacterial and parasitic infections have 893 
been linked to neurological illnesses in offspring, including cerebral palsy, autism and 894 
schizophrenia (Brown et al., 2005; Mednick et al., 1988; Nelson and Willoughby, 2000; Shi et al., 895 
2003; Sorensen et al., 2009).  Additionally, perinatal infection may increase the risk of 896 
developing neurodegenerative diseases such as Alzheimer’s and Parkinson’s later in life (Chen 897 
et al., 2011; Ling et al., 2006).  Current research suggests that it is not the infectious agent per 898 
se but the immune response that may cause neurological damage (Meyer and Feldon, 2010).  899 
Animal models of neurodevelopmental illnesses have demonstrated that perinatal immune 900 
stimulation with either infectious agents or Toll-like receptor (TLR) ligands can produce 901 
developmental and behavioral changes similar to those observed in human neurological 902 
illnesses, including alterations in learning and memory (Gilmore and Jarskog, 1997; Meyer et al., 903 
2009).  Moreover, the broad range of infectious organisms associated with 904 
neurodevelopmental dysfunction implies the etiology is not restricted to a specific organism.  905 
The fact that many immune molecules and cells have additional functions in neurological 906 
development also places unique demands on the neonatal immune system (Rolls et al., 2007; 907 
Rutkowski et al., 2010; Schafer et al., 2012; Ziv et al., 2006).  Therefore, aberrant development 908 
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may be both an outcome of the immune system acting on the nervous system and a result of 909 
altered functionality within the nervous system.     910 
A factor in how or whether perinatal infection leads to developmental abnormalities is 911 
the gestational age when insult occurs (Carvey, 2003; Meyer et al., 2006; Weinstock, 2008).  For 912 
example, fetal rats exposed to LPS demonstrate progressive dopaminergic neuron loss 913 
throughout life only when exposure occurs between embryonic days 10.5 and 11.5 (Carvey, 914 
2003; Ling et al., 2006).  While the gestational period is a particularly sensitive time for 915 
neurodevelopment, it is not known for how long after birth this sensitivity persists.  The exact 916 
relationship between age, immune response and specific developmental symptoms is not clear 917 
for many situations (Meyer and Feldon, 2010).  However, the murine immune response to 918 
neurological infection develops dramatically during the first weeks of life, with two to three 919 
week old rodents being less susceptible to infection than neonates (Couderc et al., 2008; 920 
Ryman et al., 2007; Trgovcich et al., 1999). 921 
In terms of cortical development, a newborn mouse or rat roughly corresponds to a 922 
human fetus midway through gestation (Clancy et al., 2001; Clancy et al., 2007a; Clancy et al., 923 
2007b).  Therefore, early postnatal immune activation in mice serves as a model to study the 924 
impact of infections corresponding with the mid to late gestational period in humans (Bonthius 925 
and Perlman, 2007; Hornig et al., 1999; Tohmi et al., 2007). 926 
Many, if not all, cell populations in the brain can produce inflammatory mediators such 927 
as cytokines.  As discussed in Chapter 1, both microglia and astrocytes regulate the 928 
neuroinflammatory response through production of pro- and anti-inflammatory mediators.  929 
Moreover, both microglia and astrocytes have developmental functions in the CNS [Chapter 1 930 
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and (Barres, 2008; Roumier et al., 2004; Ullian et al., 2001; Wakselman et al., 2008)].  Perinatal 931 
immune stimulation is thought to increase the risk of neurological illness by over-activating 932 
sensitive neonatal microglia [(Bilbo and Schwarz, 2009) and Chapter 1].  However, the 933 
developmental functions of astrocytes may also require neonatal astrocytes to exist in a 934 
heightened activation state under basal conditions.  In addition, and as discussed in the 935 
introduction (Chapter 1), age-specific differences in inflammatory responses have been noted in 936 
peripheral immune populations stimulated with TLR ligands (Belderbos et al., 2009; Chelvarajan 937 
et al., 2007; Ferret-Bernard et al.; Nguyen et al., 2010).  Therefore, microglia, as well as 938 
astrocytes and infiltrating peripheral immune populations, may contribute to age-associated 939 
differences in the inflammatory response in the CNS.   940 
Here we have compared neuroinflammation in neonatal and weanling mice by 941 
inoculating them with lipopolysaccharide (LPS) or CpG oligodinucleotides (CpG), ligands of TLRs 942 
4 and 9, respectively.  We measured production of pro- and anti-inflammatory mediators in 943 
brain tissue.  To better understand the processes leading to heightened neonatal inflammation, 944 
we also analyzed usage of common signaling pathways and activation of CNS immune-reactive 945 
cell populations.           946 
 947 
Results 948 
Neonatal cytokine responses to TLR4 stimulation are heightened and sustained 949 
To characterize how the cytokine response changes during the first weeks of life, we 950 
examined cytokine production in neonatal (2 day old) and weanling (21 day old) C57Bl/10 mice 951 
after intracerebral (IC) inoculation with LPS or CpG.  Control mice were either uninoculated or 952 
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inoculated IC with PBS.  LPS was used at a concentration of 0.5 µg LPS per gram of body weight, 953 
based on the average mouse weight at each age.  CpG was used at a concentration of 0.125 µg 954 
CpG (40 picomoles) per gram of body weight.  These concentrations of LPS and CpG elicit strong 955 
neonatal cytokine responses (Fig 3.1 and Fig 3.2) but are not fatal (Fig 2.1 and data not shown).     956 
We characterized the cytokine response using a multiplex bead assay, which is an 957 
antibody-based assay that simultaneously measures the protein levels of twenty common 958 
cytokines and growth factors.  Cytokine levels were calculated using in-plate standards 959 
provided by the manufacturer.  In response to intracerebral TLR9 stimulation, measured 960 
cytokine protein levels were high at 12 hpi but low or undetectable at 24, 48, 72 and 96 hpi 961 
[(Butchi et al., 2011) and data not shown].  Similarly, for detectable cytokines, IC TLR4 962 
stimulation led to strong cytokine production at 12 hpi but cytokine levels were low to 963 
undetectable at 48 and 96 hpi (data not shown).  Therefore, we compared cytokine protein 964 
levels at 12 hpi.  We focused on the 13 cytokines in the multiplex bead assay that were 965 
detectable in brain tissue.  In response to LPS, production of the inflammatory cytokines IL-1α, 966 
IL-1β, IL-2, IL-5, IL-6, TNF, CXCL9, CCL2 and CCL3 was significantly higher in neonatal brain tissue 967 
than in weanling brain tissue (Fig 3.1A).  In response to CpG, IL-2, IL-5, TNF, CXCL9 and CCL2 968 
production was elevated in neonatal brains, when compared with weanling brains.  In order to 969 
confirm our results by an additional method, IL-6 and CCL2 protein levels in neonatal and 970 
weanling brains were examined by ELISA (Fig 3.1B).  The ELISA findings agreed with trends 971 
observed in our multiplex data.   972 
Not all cytokines were up-regulated to higher levels in neonates, when compared with 973 
weanling mice.  Inflammatory cytokines whose protein levels did not show a statistically 974 
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significant age-dependent difference after TLR4 or TLR9 stimulation included IL-12, CXCL1 and 975 
CXCL10 (Fig 3.2).  However, CXCL10 expression shows the same trend in age-dependent 976 
differences that was observed for the cytokines in Figure 3.1.  Since several neonatal LPS- and 977 
CpG-treated samples were above the standard curve for CXCL10, whether or not age-978 
dependent differences in CXCL10 expression occur cannot be conclusively determined from 979 
these data.  In addition, significant age-dependent differences in the CpG response were not 980 
observed for IL-1α, IL-1β, IL-6 or CCL3.  Production of the anti-inflammatory cytokine IL-10 also 981 
did not vary significantly with age (Fig 3.2).  The multiplex bead assay also tested for IL-4, IL-13, 982 
IL-17, IFNγ and GM-CSF, but they were not present at detectable levels at either age.  In 983 
conclusion, these results indicate that TLR stimulation can provoke elevated cytokine responses 984 
in the neonatal CNS.  The cytokine response in neonates is further summarized in Table 3.1.  985 
Since the prion protein, PrPc, is developmentally expressed in the brain and may play a 986 
role in immune cell activation, we also examined cytokine production in neonatal and weanling 987 
C57Bl/10 PrP-/- mice.  Although PrPc knock out did not lead to detectable changes in the 988 
neuroimmune response (see Chapter 4), similar age-dependent differences in cytokine 989 
production were observed in both wild-type and PrP-/- mice, including age-dependent 990 
differences in IL-6, CCL2 and CXCL9 (compare Fig 4.3 with 4.4).  991 
We considered the possibility that the age-associated differences in the cytokine 992 
response reflected differences in timing, rather than the magnitude of the cytokine response 993 
(Ortega et al., 2011).  To examine this, we looked at mRNA expression levels from 2 to 48 hpi 994 
after treatment with either PBS or LPS. Significant differences in Ccl2, Ccl3 and Ifn b1 mRNA 995 
levels in PBS-treated neonatal and weanling brains were observed at 2 hpi but not at other time 996 
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points.   Age significantly influenced LPS-induced mRNA expression of Il6, Ccl2, Ccl3 and Ifn b1 997 
(Fig 3.3).  At 2 hpi after stimulation with LPS, Ccl2 and Il6 levels were comparable between the 998 
two ages.  By 6 hpi, the LPS response in weanling mice had dropped nearly to basal levels while 999 
neonatal Il6 and Ccl2 levels remained high.  In contrast, Ifn b1 levels were higher in neonates at 1000 
2 hpi but had returned to basal levels in mice of both ages by 6 hpi.  Ccl3 mRNA levels were 1001 
significantly higher in neonates than weanling mice for the duration of the response (Fig 3.3).  1002 
In summary, we observed that some cytokine mRNA levels were both prolonged and 1003 
heightened in neonates in response to immune stimulation. 1004 
 1005 
Age-dependent differences in expression of inflammatory signaling markers  1006 
We noted that basal Tlr mRNA levels in the brain and spleen increase with age (Fig 4.2), 1007 
which contrasts with the age-associated difference in ability to respond to TLR stimulation (Fig 1008 
3.1 & Fig 3.3).  To examine whether the heightened neonatal cytokine response was a global 1009 
response, we looked at gene expression in 18 common signaling pathways, including pathways 1010 
involved in inflammation, survival and development, using a Signal Transduction Pathway 1011 
Finder SuperArray.  Neonatal and weanling brain samples from PBS- and LPS-treated mice were 1012 
assessed at 6 hpi.  Among genes whose expression was altered at least two fold in response to 1013 
LPS, differences were considered to be age-associated if the LPS-stimulated response between 1014 
neonates and weanlings was statistically significant and at least two fold different.  A minimum 1015 
difference of two fold was required because each PCR cycle amplifies samples two fold, 1016 
therefore this is the limit of resolution for PCR.  Genes whose expression met these criteria are 1017 
graphed in Fig 3.4.  LPS-stimulated expression of the pro-inflammatory genes Icam1, Nos2, 1018 
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Cxcl9 and Ccl2 was significantly higher in neonates than weanling mice (Fig 3.4).  We also 1019 
noticed a trend in increased neonatal expression of Birc3, Nfkbia, Il1a, TNF and Irf1 in response 1020 
to LPS, although these age-associated differences were less than two-fold (data not shown).  1021 
Collectively, our SuperArray gene expression analysis suggested differential age-associated 1022 
regulation of the NFκB signaling pathway, which promotes inflammatory signaling downstream 1023 
of TLR stimulation (Ostuni et al., 2010). 1024 
In contrast with the elevated expression of some inflammatory markers in neonates, 1025 
Bmp4 and Csf2 levels were higher in weanling mice after stimulation with LPS (Fig 3.4).  Bmp4, a 1026 
signaling molecule critical for the development of many organs (Czyz and Wobus, 2001; 1027 
Hamilton and Anderson, 2004; Ishibashi et al., 2005), was significantly down-regulated in 1028 
neonatal, but not weanling, brains in response to LPS (p=0.0495).  Csf2, a cytokine that 1029 
promotes the differentiation of granulocytes, monocytes and dendritic cells (Hamilton and 1030 
Anderson, 2004; Hesske et al., 2010), was induced in weanling, but not neonatal, brains in 1031 
response to LPS.                                                                                                                                              1032 
 1033 
Glia contribute to the heightened neonatal response to TLR4 and TLR9 stimulation 1034 
To investigate which cell types contribute to the heightened neonatal inflammatory 1035 
response, we compared mRNA expression levels of glial markers in brain tissue from 2 to 48 hpi 1036 
(Fig 3.5A-D).  mRNA levels of the astrocytic activation marker Gfap were greater in weanling 1037 
brain tissue at 48 hpi (Figure 3.5A).  The activation marker Cd80 is expressed by myeloid cells, 1038 
including microglia, in the CNS (Hesske et al., 2010; Mausberg et al., 2009; Zhang et al., 2002).  1039 
Cd80 was significantly heightened in LPS-treated neonatal brains, when compared with 1040 
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weanling brains, at 12 hpi (Figure 3.5B).  In addition, mRNA levels of Slamf7, whose expression 1041 
we have found primarily in microglia in the CNS (Fig 3.10), were significantly higher in neonates 1042 
at 6 and 12 hours after LPS inoculation (Fig 3.5C).  In contrast, expression of the myeloid marker 1043 
F4/80 expression increased in parallel in mice of both ages at 48 hours after LPS inoculation (Fig 1044 
3.5D) (Lin et al., 2005; Lin et al., 2010). 1045 
We also considered whether a peripheral immune cell type, recruited into the brain 1046 
early in the inflammatory response, could contribute to the acute neonatal response.  We 1047 
examined mRNA levels of the T cell markers Cd3 and Cd8, the dendritic cell (DC) marker Itgax, 1048 
and the neutrophil marker Ela2.  We did not observe a significant increase in expression of any 1049 
of these markers until 48 hpi (Fig 3.5E-H).  Neonatal Ela2 expression was slightly elevated at 12 1050 
hpi but strongly induced at 48 hpi (Fig 3.5H).  In contrast, Itgax levels were higher, and relatively 1051 
stable, in neonates from 2 to 12 hpi.  However, by 48 hpi, Itgax levels were much higher in 1052 
weanling mice in response to LPS (Figure 3.5G).  Both PBS- and LPS-stimulated levels of the pan 1053 
T cell marker Cd3 were significantly higher at 48 hpi in neonatal mice (Figure 3.5E).  However, 1054 
Cd8, which is expressed by CD8+ T cells and NKT cells, was similarly induced in mice of both ages 1055 
(Fig 3.5F).  Collectively, the only cell markers that differed at early time points after LPS 1056 
stimulation were Cd80 and Slamf7.  Since both markers are expressed by microglia, these cells 1057 
may contribute to the heightened inflammatory response in neonates. 1058 
To better assess which cell types are contributing to heightened neonatal inflammation, 1059 
we separated brain tissue into two populations using a 0/30/70% Percoll gradient.  After 1060 
centrifugation, astrocytes, a cell type known to respond to TLR stimulation (Butchi et al., 2010), 1061 
are predominantly found in the 0/30% fraction [(Butchi et al., 2011) & (Fig 2.4)].  The 30/70% 1062 
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fraction contains myeloid cells, including microglia and macrophages, and infiltrating immune 1063 
cells (Peterson et al., 2006).  The immune response cannot be quantitatively compared 1064 
between the two fractions because the individual cell types that make up each fraction are 1065 
quite different.   1066 
Although basal Tlr4 expression in whole brain tissue increases with age (Fig 3.2), we did 1067 
not observe any significant age-dependent changes in Tlr4 mRNA levels in gradient fractions 1068 
enriched for either microglia or astrocytes (Fig 3.6A).  Higher overall Tlr4 mRNA levels were 1069 
found in the 30/70% fraction, when compared with the 0/30% fraction, and were strongly 1070 
down-regulated in the 30/70% fraction in response to LPS.  Tlr9 mRNA, which was also found 1071 
primarily in the 30/70% fraction, increased significantly in this fraction with age (Fig 3.6B).  We 1072 
examined Il6 and Ccl2 mRNA levels in these fractions because we previously observed age-1073 
dependent expression of these genes and their encoded proteins (Fig 3.1 & Fig 3.3).  We also 1074 
examined mRNA expression of Nos2 and Icam1 in these fractions because we found them to be 1075 
expressed at higher levels in neonates in whole brain homogenates (Fig 3.4).  Although 1076 
populations in both fractions contributed to heightened neonatal expression of these genes (Fig 1077 
3.6C-F), we observed trends towards higher IL-6 and CCL2 expression in the 30/70% fraction but 1078 
higher Nos2 and Icam1 expression in the 0/30% fraction.   1079 
 1080 
Age-associated expression of microglial activating and inhibitory proteins 1081 
To better understand the microglial contribution to neuroinflammation, we assessed 1082 
expression of microglial activating and inhibitory proteins in neonatal and weanling brains at 6 1083 
hpi.  We chose the 6 hour time point because this is when production of many cytokine mRNAs 1084 
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peak in neonates.  We sought to correlate the microglial activation profile with cytokine 1085 
production.  After IC inoculation with PBS or LPS, brain tissue was harvested, and then cells 1086 
within the 30/70% fraction of Percoll gradients were analyzed by flow cytometry. 1087 
Representative samples are shown in Figure 3.7.  Plots of forward scatter (FSC-A) versus side 1088 
scatter (SSC-A) were initially used to set cell gates that excluded dead cells and debris (Fig 3.7A-1089 
D).  Weanling cells consistently had lower side scatter than neonatal cells.  Since side scatter is a 1090 
measure of granularity, and active cells are more granular, this may be due to an increased 1091 
activity level in neonatal CNS myeloid cells.  Distinct cell populations were initially visualized 1092 
and gated on based on their expression of the leukocyte common antigen CD45 and the 1093 
myeloid-specific marker F4/80 (Fig 3.7E-H) (Irie-Sasaki et al., 2001; Lin et al., 2010).  Microglia 1094 
are known to express lower levels of CD45 than macrophages, as well as some other immune 1095 
cell populations, and so were identified as CD45lo F4/80+ (solid line in Fig 3.7E-H) (Ford et al., 1096 
1995; Sedgwick et al., 1991).  Different cell gates were required for neonatal and weanling 1097 
microglia because neonatal microglia expressed higher levels of CD45 and F4/80.  Macrophages 1098 
were identified as CD45hi F4/80+ (dotted line in Fig 3.7E-H).  Additional cells with CD45hi staining 1099 
and little to no F4/80 expression (F4/80 lo) were also observed (dashed line in Fig 3.7E-H).  1100 
Neonatal samples tended to contain larger amounts of CD45- F4/80- cells and had more intense 1101 
staining in the F4/80 (APC) channel (double solid line in Fig 3.7E-H). 1102 
We examined expression of the cell surface proteins CD11b, CD11a, CD86, CD172a, 1103 
CD200R, LY6C and SLAMF7 on CD45 high and low populations (Figures 3.8 & 3.9).  CD11a, 1104 
CD11b and CD86 are activation markers (Kettenmann et al., 2011; Kurpius et al., 2006; Liu et al., 1105 
2008).  In contrast, CD172a and CD200R inhibit activation (Gitik et al., 2011; Hernangómez et 1106 
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al., 2012; Liu et al., 2008; Masocha, 2009).  SLAMF7 can act either as an activating or inhibitory 1107 
receptor, depending on the adaptor molecules present (Cruz-Munoz et al., 2009).  LY6C 1108 
expression can help distinguish between different myeloid cell populations (Auffray et al., 2007; 1109 
Geissmann et al., 2003; Jutila et al., 1994).   1110 
In Figure 3.8, populations were color-coded to illustrate age-associated differences 1111 
CD11b and LY6C expression, as well as in side scatter and forward scatter, which is a measure of 1112 
size.  In Figure 3.8, cells within the microglial gate (solid line in Fig 3.7E-H) are blue, 1113 
macrophages (dotted line in Fig 3.7E-H) are green, and CD45hi F4/80lo cells (dashed line in Fig 1114 
3.7E-H) are pink and aqua.  CD45- F4/80- cells are yellow (double solid line in Fig 3.7E-H).  The 1115 
phenotypes of these cell populations are summarized in Table 3.2.  When cells were plotted 1116 
based on CD45 and CD11b expression, the CD45hi F4/80lo cells could be separated into two 1117 
distinct populations with CD11b high and low expression, which segregated to either side of the 1118 
macrophage population (Fig 3.8 B & F).  The CD45hi F4/80lo CD11bhi cells are pink while the 1119 
CD45hi F4/80lo CD11blo cells are aqua.  In the CD45hi F4/80lo population, CD11b expression also 1120 
correlated with LY6C expression (Fig 3.8 D & H).  Examination of F4/80 expression on CD45hi 1121 
F4/80lo cells in which the CD11bhi and CD11blo populations were separately colored 1122 
demonstrated that both of these populations had variable F4/80 expression (Fig 3.8 C & G).  1123 
Macrophages expressed an intermediate amount of CD11b, high levels of LY6C, and were larger 1124 
and of intermediate granularity (Fig 3.8 A & E).  Microglia were similar to the CD45hi F4/80lo 1125 
CD11blo cells in their size, granularity, and expression of CD11b and LY6C (Fig 3.8).  CD45hi 1126 
F4/80lo CD11bhi cells were the least uniform in size and granularity.  Neonatal samples 1127 
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contained fewer macrophages and CD45hi F4/80lo CD11blo cells, but more CD45- F4/80- cells, 1128 
than weanling samples.   1129 
In neonatal PBS-treated samples, we also observed a population of cells with very high 1130 
forward and side scatter (Fig 3.8 A, dashed red line).  Gating on this population shows an 1131 
additional population of cells in graphs of antibody staining (CD45, F4/80, CD11b, LY6C) that are 1132 
always to the upper right of the CD45hi F4/80lo CD11blo population (pink) for all antibodies (data 1133 
not shown), indicating proportionally higher staining for these antibodies.   These cells could be 1134 
doublets or an additional, uncharacterized population. 1135 
Based on the greater overall responsiveness of neonates to neuroinflammatory stimuli, 1136 
we expected to observe increased expression of activation markers and decreased expression 1137 
of inhibitory receptors on neonatal microglia in response to LPS, when compared with weanling 1138 
microglia.  Indeed, expression of the activation markers CD11a and CD11b was consistently 1139 
higher on neonatal microglia when compared with weanling microglia (Fig 3.9 A-C).  1140 
Unexpectedly, expression of the inhibitory receptor CD172a was also higher on neonatal 1141 
microglia than weanling microglia.  In addition, these microglial protein levels did not 1142 
significantly change in response to LPS in mice of either age (Fig 3.9 D-F), possibly due to the 1143 
early time point post-treatment (6 hpi).  Significant age-dependent differences in levels of the 1144 
activation marker CD86 and in inhibitory CD200R were not observed in microglia (data not 1145 
shown).   1146 
SLAMF7 has been shown to be expressed by a variety of peripheral immune populations 1147 
(Beyer et al., 2012; Cruz-Munoz et al., 2009; Llinas et al., 2011).  However, SLAMF7 expression 1148 
on microglia has not previously been described.  After observing elevated Slamf7 expression in 1149 
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neonatal whole brain homogenates in response to LPS (Fig 3.5C), we examined Slamf7 1150 
expression in the 0/30% and 30/70% fractions of centrifuged neonatal and weanling Percoll 1151 
gradients (Fig 3.10A).  In response to LPS stimulation, Slamf7 was primarily up-regulated in the 1152 
neonatal 30/70% fraction.  Slamf7 expression was also up-regulated in the weanling 30/70% 1153 
fraction in response to stimulation with CpG.  We looked at SLAMF7 expression on CD45+ 1154 
populations (Fig 3.10B) and found that SLAMF7 protein levels were higher on neonatal 1155 
microglia than on all other populations examined (p < 0.0001), although it was not elevated 1156 
following LPS stimulation.   1157 
Collectively, our flow cytometry data suggest there may be differences in the ratios of  1158 
CD45hi populations in neonatal and weanling brains, based on expression of CD11b and LY6C.  1159 
This difference could contribute to the differing cytokine responses observed at each age.  Our 1160 
data also suggest that there are age-associated differences in expression of CD11a, CD11b, 1161 
CD172a and SLAMF7 on microglia. 1162 
We also examined expression of CD11b and CD45 in the spleen.  The spleen serves as 1163 
the primary reservoir for monocytes (Swirski et al., 2009).  In response to immune stimulation, 1164 
splenic monocytes migrate into tissues and differentiate into macrophages and dendritic cells 1165 
(Geissmann et al., 2010; Swirski et al., 2009).  Although we did not observe LPS-specific 1166 
differences in the CNS at 6 hpi by flow cytometry, CD11b was up-regulated in the spleen in an 1167 
LPS-dependent manner at this time point (Fig 3.11).  In addition, CD45 expression was up-1168 
regulated on LPS-stimulated CD11b+ spleen cells.  This suggests that the peripheral immune 1169 
response to TLR4 agonist inoculation in the brain is detectable at least as early as 6 hpi.  There 1170 
were no age-dependent differences in splenic CD11b or CD45 expression.     1171 
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 1172 
Discussion 1173 
The immune response at birth is immature and infants are often unable to mount an 1174 
effective response to infection (Levy, 2007).  Therefore, we were initially surprised to find that 1175 
some cytokine levels were higher in neonatal brains than weanling brains in response to TLR4 1176 
and TLR9 stimulation.  However, as detailed in Chapter 1, recent studies in peripheral tissues 1177 
and immune cells have demonstrated that age-associated differences in cytokine production 1178 
can also differ based upon the cell or tissue type being examined (Aksoy, 2006; Chelvarajan et 1179 
al., 2007; Chelvarajan et al., 2004; Ferret-Bernard et al.; Islam et al., 2012b).  In addition, the 1180 
immune response is uniquely regulated in the brain (Carson et al., 2006; Ransohoff and 1181 
Cardona, 2010).  Therefore, conclusions about the neonatal TLR response in the brain cannot be 1182 
inferred from studies of other tissues.   1183 
Our results extend current knowledge of the neonatal neuroinflammatory response by 1184 
directly comparing the responses of neonatal and weanling mice to TLR4 or TLR9 stimulation.  1185 
We demonstrate that production of many cytokines is higher in neonatal brains than in 1186 
weanling brains. TLR4 stimulation in neonates leads to elevated production of cytokines that 1187 
are an important part of the inflammatory response in many neurological conditions, including 1188 
the cytokines IL-1β, TNF and IL-6.  TLR9 stimulation also led to increased neonatal cytokine 1189 
expression, albeit for a smaller subset of cytokines.  Our research suggests some cytokine 1190 
responses to TLR stimulation in the brain are elevated in neonates.  This includes higher 1191 
neonatal levels of IL-1b, TNF and Cxcl9, cytokines whose expression is often inhibited during the 1192 
neonatal TLR response in the periphery (Angelone et al., 2006; Chelvarajan et al., 2004; Islam et 1193 
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al., 2012a; Levy et al., 2006a; Nguyen et al., 2010).  In contrast, we were unable to detect 1194 
significantly higher neonatal levels of IL-10, an anti-inflammatory cytokine whose production is 1195 
often elevated in neonatal peripheral immune cells (Chelvarajan et al., 2007; Ferret-Bernard et 1196 
al.; Martino et al., 2012).  IL-12, which is often expressed at reduced levels in neonatal 1197 
responses to TLR stimulation in the periphery (Belderbos et al., 2009; Chelvarajan et al., 2004; 1198 
Islam et al., 2012a), did not differ significantly with age in the brain.  Thus, the neonatal 1199 
response in brain tissue appears to differ from that reported for peripheral tissues. 1200 
Although elevated levels of IL-6, IL-1β and TNF in the neonatal brain have been 1201 
correlated with later cognitive disability and behavioral changes (Bilbo and Schwarz, 2009), few 1202 
published studies directly compare the neuroinflammatory response of neonates with that of 1203 
older animals.  Ortega et al. recently examined cytokine responses in the brains of neonatal and 1204 
weanling rats to intraperitoneal LPS administration (Ortega et al., 2011).  They found that 1205 
mRNA levels of Il-6, Il-1β and Tnf peak at 2-6 hpi in weanling brains, but peak at 6-24 hpi in 1206 
neonatal brains.  In contrast, we did not find that cytokine mRNA expression in response to IC 1207 
LPS occurred sooner in weanling mice.  However, we did observe that for the cytokine mRNAs 1208 
examined, expression was prolonged in neonatal mice.  Therefore, whether age-dependent 1209 
differences in the timing of the CNS cytokine response occur may be influenced by either the 1210 
location or the trafficking of the immune stimulus in the body.     1211 
As described in Chapter 1, altered activation and expression of molecules involved in 1212 
TLR signaling has been implicated in distinct neonatal immune responses in the periphery (Levy, 1213 
2007).  In parallel with this, we noted heightened CD11b levels on neonatal microglia when 1214 
compared with weanling microglia.  CD11b is thought to be involved in TLR4 signaling by aiding 1215 
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the recruitment of intracellular TLR signaling adaptor proteins to lipid rafts, where LPS-bound 1216 
TLR4 is localized (Chapter 1).  Therefore, elevated microglial CD11b levels could promote 1217 
neonatal TLR4 signaling. 1218 
In addition to increased microglial CD11b protein levels, CD11a protein levels on 1219 
microglia and CD11c (Itgax) mRNA levels in whole brain tissue were also increased in neonates.  1220 
CD11a, CD11b and CD11c belong to the β2-integrin family of adhesion molecules.  Increased 1221 
neonatal expression of β2-integrins supports the theory that neonatal microglia exist in a 1222 
heightened activation state because β2-integrins are involved in migration and phagocytosis (Hu 1223 
et al., 2010; Liu et al., 2008).  Our observations on the age-associated changes in β2-integrin 1224 
expression on microglia agree with the morphological studies of others (see Chapter 1) and 1225 
suggest that neonatal microglia are in a more active state under basal conditions than microglia 1226 
from older animals.   1227 
We were initially surprised that CD11a and CD11b levels did not change in response to 1228 
TLR4 stimulation.  However, we examined the protein levels of microglial activation markers at 1229 
the early time point of 6 hpi.  In a study of the neonatal microglial response to neuronal 1230 
damage, new protein synthesis was not required for early microglial responses, including 1231 
migration (Kurpius et al., 2006).  This implies that proteins involved in microglial migration, such 1232 
as CD11a and CD11b, exist at high enough levels under homeostatic conditions to allow 1233 
neonatal microglia to begin to respond to trauma without waiting for new proteins to be 1234 
synthesized.  While microglial activation in response to other stimuli was not examined, it may 1235 
be that new protein synthesis is not required for the early response of neonatal microglial to 1236 
LPS.  If protein synthesis is not required for the initial changes in microglia associated with 1237 
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activation, this may explain why we observe age-dependent, but LPS-independent, changes in 1238 
microglial activation markers involved in adhesion and migration.   1239 
In addition to increased expression of some pro-inflammatory mediators in neonates, 1240 
we observed increased expression of the anti-inflammatory mediator CD172a in neonates.  1241 
CD172a negatively regulates CD11b-mediated adhesion, migration and phagocytosis (Liu et al., 1242 
2008).  Heightened CD172a expression could provide a counterbalance to the elevated levels of 1243 
β2-integrins on neonatal microglia.   1244 
We found SLAMF7 expression in the brain to be of particular interest because SLAMF7 1245 
levels were highest on neonatal microglia.  Microglia express lower levels of many immune 1246 
receptors than other macrophage populations (Ransohoff and Cardona, 2010).  Therefore, it is 1247 
somewhat surprising that we detected the highest SLAMF7 expression on neonatal microglia.  1248 
SLAMF7 was the only immune cell marker examined in this study whose expression was higher 1249 
on microglia than on all other cell populations examined.  As mentioned above, SLAMF7 can be 1250 
either an activating or inhibitory receptor.  The activity of SLAMF7 on microglia is not yet clear. 1251 
We observed age-dependent differences in the CNS immune populations found in the 1252 
brain.  Neonatal samples contained fewer macrophages and CD45hi F4/80lo CD11blo cells than 1253 
weanling samples.   The identities of the CD45hi F4/80lo CD11bhi and CD11blo populations are 1254 
unclear.  They may include monocytes, as circulating monocytes have been shown to express 1255 
lower levels of F4/80 than tissue resident macrophages (Lin et al., 2010).  However, the CD45hi 1256 
populations could also include T cells, neutrophils and DCs.  Other studies have noted small 1257 
endogenous populations of dendritic cells, T cells and neutrophils in murine and primate brains 1258 
under homeostatic conditions (Bischoff et al., 2011; Dick et al., 1995; Ford et al., 1995; 1259 
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Gottfried-Blackmore et al., 2009).  In addition, intracerebral immune stimulation can lead to a 1260 
large influx of peripheral immune cells, including DCs (Gelderblom et al., 2009; Hesske et al., 1261 
2010; Mausberg et al., 2009).   1262 
The number of CD45hi cells detected in LPS-treated samples was reduced when 1263 
compared with PBS-treated samples.  These results were observed in both neonatal and 1264 
weanling tissues.  It is unclear why fewer CD45hi cells were detected in LPS-stimulated samples 1265 
because immune stimulation is expected to increase recruitment of peripheral immune cells.  1266 
Montero-Menei et al. reported a similar phenomenon in rats that were either inoculated IC 1267 
with LPS or received an IC stab lesion (Montero-Menei et al., 1996).  At 5 hpi, greater infiltration 1268 
of CD11b+ cells was observed in the stab lesioned brains than in the LPS inoculated brains.  1269 
However, at 15 hours and later there was greater CD11b+ infiltration into LPS-treated brains 1270 
than into stab lesioned brains (Montero-Menei et al., 1996).  If IC LPS initially suppresses 1271 
immune cell recruitment but later promotes it, as suggested by Montero-Menei et al., then LPS-1272 
specific recruitment of peripheral immune cells could also be delayed in our model.  1273 
In neonatal PBS-treated samples we also observed a population of cells with very high 1274 
forward and side scatter (dashed red line in Fig 3.8 A).  This population may include doublets, 1275 
perhaps due to the rapid cell division occurring at this age.  Alternatively, this could be a distinct 1276 
population of cells.  1277 
We found that mRNA levels of the astrocyte activation marker Gfap were higher in 1278 
weanling mice.  However, we suspect that, in this situation, Gfap expression does not 1279 
accurately reflect the activation state of neonatal astrocytes.  Gfap is an intermediate filament 1280 
protein involved in cytoskeletal structure.  Gfap levels may more accurately reflect that 1281 
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weanling astrocytes have more, and larger, processes than neonatal astrocytes.  We expect that 1282 
astrocytes contribute to the elevated inflammatory response observed in neonatal brains 1283 
because astrocytes are a component of the 0/30% Percoll gradient fraction, which contributes 1284 
to the elevated neonatal response.  Other cells, such as oligodendrocytes or ependymal cells, 1285 
may also contribute to the inflammatory response observed in the 0/30% fraction. 1286 
In addition to shedding light on the etiology of neurodevelopmental disorders, a better 1287 
understanding of the unique pro- and anti-inflammatory aspects of the neonatal immune 1288 
response may lead to the development of more effective treatments for the initial infection as 1289 
well as its long term consequences. 1290 
 1291 
 1292 
 1293 
 1294 
 1295 
 1296 
 1297 
 1298 
 1299 
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 1301 
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Table 3.1 Age-associated changes in cytokine responses. 1304 
 Overall significant  
interaction between  
age and treatment? 
Change in 
  response to  
LPS 
Neonatal 
response to  
CpG 
IL-2 Y ↑* ↑* 
IL-5 Y ↑* ↑* 
TNF Y ↑* ↑* 
CCL2 Y ↑* ↑* 
CXCL9 Y ↑* ↑* 
IL-1a Y ↑* ↔ 
IL-1b Y ↑* ↔ 
IL-6 N ↑* ↔ 
CCL3 N ↑* ↔ 
IL-10 N ↔ ↔ 
IL-12 N ↔ ↔ 
CXCL1 N ↔* ↔ 
CXCL10 N ↔* ↔* 
 1305 
Overall significant interactions between age and treatment are listed in the first column.  1306 
Arrows indicate direction of response in neonates when compared with weanling mice.  1307 
Asterisk indicates whether cytokine was significantly induced in neonates in response to the 1308 
given agonist.  Statistical analysis was completed by two-way analysis of variance with Sidak’s 1309 
multiple comparisons test. 1310 
 1311 
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Table 3.2 Phenotypes of examined cell populations. 1312 
Population 
Color in 
Figure 3.8 
 
Microglia Blue CD45
lo
 F4/80
+
 CD11b
lo
 Ly6C 
-
 SSC
lo
 
Macrophages Green CD45
hi
 F4/80
+
 CD11b
int
 Ly6C
hi
 SSC
int
 
Other cell populations: 
Unknown Pink CD45
hi
 F4/80
lo
 CD11b
hi
 Ly6C
hi
 SSC
hi
 
Unknown Aqua CD45
hi
 F4/80
lo
 CD11b
lo
 Ly6C 
-
 SSC
lo
 
Unknown Yellow CD45
-
 F4/80
-
 CD11b
lo
 Ly6C
-
 n.d. 
n.d. = not determined 1313 
 1314 
 1315 
 1316 
 1317 
 1318 
 1319 
 1320 
 1321 
 1322 
 1323 
 1324 
 1325 
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Table 3.3 Percentage of cells in examined populations. 1326 
 Color in 
Figure 3.8 
2 d, PBS 2 d, LPS 21 d, PBS 21 d, LPS 
Microglia Blue 20.1 ± 7.4 43.2 ± 3.7 56.3 ± 7.2 79.1 ± 6.0 
Macrophages Green 2.0 ± 0.2 1.8 ± 0.4 13.1 ± 1.5 3.2 ± 0.9 
Unknown 
CD11bhi 
Pink 58.2 ± 8.9 15.9 ± 0.3 19.6 ± 7.4 4.8 ± 0.9 
Unknown 
CD11blo 
Aqua 0.5 ± 0 0.5 ± 0.2 3.6 ± 0.8 0.7 ± 0.1 
CD45- Yellow 15.6 ± 0.8 35.6 ± 4.4 3.8 ± 0.7 6.9 ± 3.8 
 1327 
 1328 
 1329 
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1330 
Figure 3.1 Heightened neonatal cytokine responses to IC TLR4 and TLR9 stimulation.  Neonatal 1331 
(2 d.o.) and weanling (21 d.o.) mice were inoculated intracerebrally (IC) with LPS or CpG.  1332 
Control groups were either not inoculated or inoculated IC with PBS.  (A) Cytokine protein levels 1333 
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in brain homogenates from neonatal and weanling mice were measured at 12 hpi using a 1334 
multiplex bead assay.  n = 10-12 for 2 d.o. mice and includes the combined results from two 1335 
independent experiments, n = 5-6 for 21 d.o. mice from one independent experiment.  (B) Age-1336 
dependent differences in cytokine production were confirmed by ELISA for IL-6 and Ccl2.  n = 5 1337 
mice per group.  Data are presented as mean +/- SD.  For both assays, protein concentrations 1338 
were calculated using in-plate standard curves derived from manufacturer-provided protein 1339 
standards.  Dotted line indicates lower limit of detection (based on standard curve).  # indicates 1340 
treatment group contains samples above the dynamic range (based on standard curve).  1341 
Outliers detected by Grubbs’ test were excluded.  Statistical analysis was completed by two-1342 
way analysis of variance with Sidak’s multiple comparisons test.  Significant age-specific 1343 
differences are as indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 1344 
 1345 
 1346 
 1347 
 1348 
 1349 
 1350 
 1351 
 1352 
 1353 
 1354 
 1355 
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 1356 
Figure 3.2 Production of some cytokines does not differ with age in response to IC LPS or CpG.  1357 
Neonatal and weanling mice were inoculated IC with PBS, LPS or CpG, or remained 1358 
uninoculated.  Cytokine protein levels in whole brain homogenates were measured at 12 hpi 1359 
using a multiplex bead assay.  n = 10-12 for 2 d.o. mice and includes the combined results from 1360 
two independent experiments, n = 5-6 for 3 w.o. mice from one independent experiment.  1361 
Dotted line indicates lower limit of detection (based on standard curve).  # indicates treatment 1362 
group contains samples above the dynamic range (based on standard curve).  Outliers detected 1363 
by Grubbs’ test were excluded. Statistical analysis was completed by two-way analysis of 1364 
variance and Sidak’s multiple comparisons test.  Data are presented as mean +/- SD.   1365 
 1366 
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 1367 
Figure 3.3 Heightened and prolonged inflammatory cytokine responses in neonates.  Cytokine 1368 
mRNA levels in whole brain homogenates from neonatal and weanling mice were assayed at 2, 1369 
6, 12 and 48 hpi after IC inoculation with PBS or LPS.  n = 4-6 mice per group.  No statistically 1370 
significant differences in Il6 levels were observed between PBS treated neonatal and weanling 1371 
mice.  Neonatal PBS treated mice expressed significantly higher levels of Ccl2, Ccl3 and Ifn β1 1372 
than weanling PBS treated mice at 2 hpi only (p=0.0339 for Ccl2, p=0.0143 for Ccl3, p=0.0075 1373 
for Ifn β1).  Data are presented as mean +/- SE.  Statistical analysis was completed by two-way 1374 
analysis of variance with Tukey’s multiple comparisons test.  Significant age-specific differences 1375 
in the LPS response are indicated in the figure as:  **p<0.01, ***p<0.001, ****p<0.0001. 1376 
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 1377 
Figure 3.4 Age-associated differences in expression of signaling markers.  Age-dependent 1378 
differences in the LPS response were analyzed using a PCR SuperArray designed to detect 1379 
differential usage of 18 common signaling pathways, including pathway involved in 1380 
inflammation, survival and development.  mRNA expression levels in whole brain homogenates 1381 
of neonatal and weanling mice were tested at 6 hpi with PBS or LPS.  Data presented here 1382 
include genes whose expression showed a statistically significant change in response to both 1383 
LPS and age.  n = 4 mice per group.  Data are presented as mean +/- SD.  Statistical analysis was 1384 
completed by two-way analysis of variance with Tukey’s multiple comparisons test.  Significant 1385 
age-specific differences are as indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 1386 
 1387 
 1388 
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 1389 
Figure 3.5 Temporal expression of glial and immune cell markers after TLR4 stimulation.  1390 
mRNA levels of glial and immune cell markers in whole brain homogenates from neonatal and 1391 
weanling mice were tested at 2, 6, 12 and 48 hpi with PBS or LPS.  (A) mRNA levels of the 1392 
astrocytic marker Gfap are higher in weanling mice.  (B) Cd80, which is expressed by microglia 1393 
and macrophages in the CNS, is induced early in the inflammatory response, and to a greater 1394 
degree, in neonates.  (C) Slamf7, which is expressed by microglia, is also induced early, and to a 1395 
greater degree, in neonates.  (D) The myeloid marker F4/80 is not strongly induced until 48 hpi 1396 
and is not induced in an age-specific manner.  (E) Neonatal expression of the pan T cell marker 1397 
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Cd3 is higher under mock- and LPS-inoculated conditions at 48 hpi.  (F) No age-associated 1398 
differences were observed for Cd8, which is expressed by a T cell subset and NKT cells.  (G) The 1399 
dendritic cell marker Itgax is expressed at higher levels in neonates at early time points, but not 1400 
significantly more in response to LPS.  At 48 hpi, Itgax levels are significantly higher in LPS-1401 
stimulated weanling mice.  (H) The neutrophil marker Ela2 is expressed at higher levels in 1402 
neonates in response to LPS at 12 and 48 hpi.  No statistically significant differences in Cd80, 1403 
F4/80, Slamf7, Gfap, Cd8 or Ela2 levels were observed between PBS-treated neonatal and 1404 
weanling mice.  Cd3 levels were significantly higher in PBS-treated neonates than in weanling 1405 
mice at 48 hpi.  Itgax levels were significantly higher in neonates in response to PBS at 2, 6 and 1406 
12 hpi.  n = 4-6 mice per group.  Data are presented as mean +/- SE.  Statistical analysis was 1407 
completed by two-way analysis of variance with Tukey’s multiple comparisons test.  Significant 1408 
age-specific differences in the LPS response are as indicated: *p<0.05, **p<0.01, ***p<0.001, 1409 
****p<0.0001 1410 
 1411 
 1412 
 1413 
 1414 
 1415 
 1416 
 1417 
 1418 
 1419 
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 1420 
 1421 
Figure 3.6 Both astrocyte- and microglia-enriched fractions contribute to heightened neonatal 1422 
expression of inflammatory genes.  At 6 hours after IC inoculation with PBS, LPS, or CpG, brain 1423 
homogenates from neonatal and weanling mice were fractionated on Percoll gradients, and 1424 
mRNA expression levels were analyzed by qRT-PCR.  (A & B) Tlr4 and Tlr9 are predominantly 1425 
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expressed in the 30/70 % fraction, which is enriched for microglia.  (A)  Tlr4 levels did not vary 1426 
with age.  LPS stimulation leads to significant down-regulation of Tlr4 in neonatal and weanling 1427 
30/70 % fractions (p<0.0001).  A similar trend in Tlr4 down-regulation is observed in the 0/30% 1428 
fraction, which is enriched for astrocytes.  (B)  Under all conditions tested, Tlr9 expression 1429 
significantly increases with age in the 30/70 % fraction.  (C) Il6 production is significantly higher 1430 
in the neonatal 30/70% fraction, when compared with weanling mice.  (D) Ccl2 expression is 1431 
significantly elevated under all conditions in neonatal 30/70% fractions, as well as the neonatal 1432 
0/30% fraction in response to LPS.  (E) In response to LPS, iNOS levels are significantly higher in 1433 
both neonatal fractions than in weanling fractions.  In response to CpG, the 0/30% fraction 1434 
expresses significantly higher iNOS mRNA levels in neonates.  (F) Icam1 expression is 1435 
significantly higher in LPS-stimulated 0/30% fractions.  n = 4-5 per group.  Data are presented as 1436 
mean +/- SD.  Statistical analysis was completed by two-way analysis of variance with Tukey’s 1437 
multiple comparisons test.  Significant age-specific differences in the response to LPS or CpG 1438 
are as indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 1439 
 1440 
 1441 
 1442 
 1443 
 1444 
 1445 
 1446 
 1447 
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 1448 
 1449 
Figure 3.7 Cell population gates used for analysis by flow cytometry.  At 6 hours after 1450 
inoculation, samples were isolated on Percoll gradients, then analysis of CNS immune cell 1451 
populations was performed using flow cytometry.  (A-D) Side scatter (SSC) and forward scatter 1452 
(FSC) were used to create cell gates and exclude debris and apoptotic cells (gate shown).  Cell 1453 
populations were separated by their expression of CD45 and F4/80.  (E-H) Microglia were 1454 
identified as CD45lo F4/80+ (solid line).  Macrophages were identified as CD45hi F4/80+ (dotted 1455 
line).  Other immune cells were CD45hi F4/80lo (dashed line).  Unstained cells were CD45- F4/80- 1456 
(double line).  Representative samples are shown. (A & E) 2 d.o., PBS IC; (B & F) 2 d.o., LPS IC; (C 1457 
& G) 21 d.o., PBS IC; (D & H) 21 d.o., LPS IC.  Circles are for illustrative purposes only and are 1458 
not the actual cell gates. 1459 
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 1460 
Figure 3.8 CNS immune cell populations.  Cell populations could be further distinguished by 1461 
their (A & E) side and forward scatter, (B & F) CD11b and (D & H) Ly6C expression. (C & G) 1462 
F4/80 expression is also shown. (B-D, F-H)  For reference, all samples were plotted against CD45 1463 
expression on the y-axis. Representative samples from PBS-treated mice are shown. (A-D) 1464 
Neonatal; (E-H) Weanling.  Cell populations are color-coded: CD45lo F4/80+ microglia (blue), 1465 
CD45hi F4/80+ macrophages (green), CD45hi F4/80 lo immune cells (aqua and pink), CD45- F4/80- 1466 
cells (yellow).  1467 
 1468 
 1469 
 1470 
 1471 
 1472 
 1473 
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 1474 
Figure 3.9 Increased expression of activating and inhibitory markers on neonatal microglia.  1475 
Microglial populations were analyzed ex vivo at 6 hpi after IC PBS or LPS inoculation.   Neonatal 1476 
microglia exhibit increased expression of (A & D) CD11b, (B & E) CD11a and (C & F) CD172a.  1477 
Histograms in (A-C) show representative PBS-treated neonatal and weanling samples, as well as 1478 
unstained control.  Mean fluorescence intensity (MFI) after PBS or LPS treatment is plotted for 1479 
each antigen in (D-F).  Protein levels differed significantly in an age-dependent, but LPS-1480 
independent, manner at this time point.   Data was reproduced in an additional experiment 1481 
that used lower antibody concentrations.  n = 2-3 mice per group.  Data are presented as mean 1482 
+/- SD.  Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple 1483 
comparisons test.  Significant age-specific differences are as indicated: **p<0.01, ***p<0.001, 1484 
****p<0.0001 1485 
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 1486 
Figure 3.10 SLAMF7 is strongly expressed by neonatal microglia. (A) Slamf7 expression in 1487 
neonatal and weanling Percoll gradient fractions in shown at 6 hours after IC stimulation with 1488 
PBS, LPS or CpG.  Slamf7 was significantly induced in the neonatal 30/70% LPS-stimulated 1489 
fraction.  A similar trend was observed, but to a lesser extent, in the weanling 30/70% CpG-1490 
stimulated fraction.  Statistical analysis was completed by two-way analysis of variance with 1491 
Tukey’s multiple comparisons test.  n=4-5 per group.  (B) SLAMF7 mean fluorescence intensity 1492 
(MFI) for neonatal and weanling populations separated by CD45 and F4/80 staining (see Figure 1493 
3.7).  ‘Unknown’ refers to CD45hi population.  Expression of SLAMF7 was significantly elevated 1494 
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in neonatal microglia when compared with other populations shown (p<0.0001).  Statistical 1495 
analysis was completed by two-way analysis of variance with Dunnett’s multiple comparisons 1496 
test and Tukey’s multiple comparisons test.  n=2-3 per group. 1497 
 1498 
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 1506 
Figure 3.11 Increased expression of CD11b in the spleen after IC LPS.  Forward scatter and side 1507 
scatter were used to gate on cells (red line) in the spleen.  CD11b expression is shown for 1508 
representative neonatal and weanling spleen samples after IC treatment with PBS or LPS.  CD45 1509 
expression is shown for CD11b+ populations only.  Splenic CD11b and CD45 expression was 1510 
analyzed in two independent experiments in weanling mice and one experiment in neonatal 1511 
mice.   1512 
 1513 
 1514 
 1515 
 1516 
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CHAPTER FOUR 1517 
PRION PROTEIN AND THE NEUROINFLAMMATORY RESPONSE  1518 
TO TOLL-LIKE RECEPTOR 4 AND 9 STIMULATION IN YOUNG MICE 1519 
Introduction 1520 
PrPc is expressed in most tissues but expression is highest in neurons (Bendheim et al., 1521 
1992).  There are also significant PrPc levels in microglia, astrocytes and many peripheral 1522 
immune cell types (Arantes et al., 2009; Brown et al., 1998; Dodelet and Cashman, 1998; J. D. 1523 
Isaacs, 2006).  PrPc is developmentally regulated (Lazarini et al., 1991; Lieberburg, 1987; 1524 
Manson et al., 1992; Moser et al., 1995) and influences neuronal survival, astrocyte 1525 
development, and the acute stress response (Arantes et al., 2009; Lima et al., 2007; Nico et al., 1526 
2005).  However, PrP knock out (PrP-/-) mice do not exhibit any gross phenotypic abnormalities 1527 
(Bueler et al., 1992; Manson et al., 1994) and the precise role of PrPc remains poorly defined.   1528 
PrPc expression is differentially regulated in activated immune cells and influences 1529 
several aspects of immune cell function.  PrPc expression regulates macrophage phagocytosis 1530 
and stimulates signaling pathways involved in phagocytosis, cellular migration and cytokine 1531 
production in vitro (de Almeida et al., 2005; Krebs et al., 2006).  Dendritic cell expression of PrPc 1532 
is required for dendritic cell activation of T cells (Ballerini et al., 2006).  In vivo, PrPc expression 1533 
alters macrophage phagocytosis and recruitment of immune cells to the site of inflammation in 1534 
the periphery (de Almeida et al., 2005).  Several papers report altered cytokine production in 1535 
PrP-/- tissues and cells, including reduced production of TNF in injured PrP-/- muscles, less IL-2 1536 
and IL-4 production by stimulated PrP-/- splenocytes, and increased IL-6 expression in inflamed 1537 
PrP-/- colons (Bainbridge and Walker, 2005; Martin et al., 2011; Stella et al.).   1538 
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Despite the high expression of PrPc in the central nervous system (CNS) and the 1539 
influence of PrPc over the immune response, research examining the role of PrPc in the 1540 
neuroimmune response is limited.  In cultured microglia, PrPc expression is proportional to the 1541 
degree of microglial proliferation and activation, with PrP-/- microglia being the least responsive 1542 
to activation (Brown et al., 1996; Brown et al., 1998; Herms et al., 1997).  Nasu-Nishimura et al. 1543 
reported that PrP-/- mice infected with encephalomyocarditis viral (ECMV) display reduced 1544 
microglial activation and recruitment of peripheral immune cells into the brain when compared 1545 
with wild-type (WT) mice (Nasu-Nishimura et al., 2008). PrPc exerts a neuroprotective effect in 1546 
the CNS in response to sterile inflammation caused by ischemia (McLennan et al., 2004; 1547 
Sakurai-Yamashita et al., 2005). 1548 
In the present study, we examined how PrPc influences the neuroinflammatory response 1549 
in vivo using a model system that activates Toll-like receptor (TLR) signaling pathways.   TLRs 1550 
activate the innate immune system through binding to conserved molecular patterns 1551 
associated with both infection and sterile inflammation.  We chose to use the TLR9 ligand, CpG-1552 
rich DNA (CpG), and the TLR4 ligand, lipopolysaccharide (LPS), both of which also bind PrPc.  1553 
PrPc binds nucleic acids with high affinity but low specificity (Cordeiro et al., 2001; Gabus et al., 1554 
2001; Weiss et al., 1997).  DNA binding leads to conformational changes and aggregation of the 1555 
prion protein (Cordeiro et al., 2001; Nandi et al., 2002; Yin et al., 2008).  Additionally, nucleic 1556 
acid and phosphorothioated nucleic acid binding to prion protein causes internalization of the 1557 
PrP:DNA complex while PrPc expression promotes uptake of DNA (Kocisko et al., 2006; Yin et al., 1558 
2008).  Such molecules can also strongly influence conversion of PrPc to PrPSc both in vivo and in 1559 
vitro (Cordeiro et al., 2001; Deleault et al., 2003; Kocisko et al., 2006).  LPS binds PrPc under 1560 
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conditions of normal and low pH (Pasupuleti et al., 2009) and is reported to up-regulate PrPc 1561 
expression in spleens, as well as in macrophage and microglial cell lines (Gilch et al., 2007; 1562 
Lotscher et al., 2007).   1563 
Here, we have tested whether PrPc influences cytokine production and glial activation in 1564 
response to TLR stimulation with LPS or CpG by comparing responses in WT, PrP-/-, and Tg7 1565 
mice.  In Tg7 mice, mouse prion protein has been knocked out and hamster prion protein, 1566 
which is similar in sequence, in expressed at three to four fold higher levels than normal.  We 1567 
examined these responses shortly following birth, when mice are undergoing rapid neurological 1568 
development, and at 21 days, when physiological levels of PrPc are higher in the brain.   1569 
 1570 
Results 1571 
PrPc expression in the brain changes with age but not in response to LPS or CpG stimulation 1572 
As the PrP-/- mice that we used had been bred extensively onto the C57Bl/10 1573 
background, we used WT C57Bl/10 mice as our PrPC positive controls.  Tg7 PrPc overexpressing 1574 
mice were also on a C57Bl/10 background and overexpress hamster PrPc, which is similar in 1575 
sequence to mouse PrPc.  We examined the neuroinflammatory response in neonatal (2 d.o.) 1576 
and weanling (21 d.o.) mice because the developmental increase in brain Prnp expression 1577 
leveled off at 21 days of age in C57Bl/6 mice (Lazarini et al., 1991).  However, when we later 1578 
looked at Prnp mRNA levels in WT C57Bl/10 mice from 2 to 42 days of age using quantitative 1579 
real-time PCR (qRT-PCR), we observed that basal brain Prnp levels continued to rise over the 1580 
entire time period examined (Fig 4.1A).  Although C57Bl/10 Prnp levels increased approximately 1581 
five-fold in the brain in the first six weeks of life, Prnp levels in the peripheral immune organs of 1582 
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the spleen and thymus remained constant over this period (Fig 4.1A).  We also examined 1583 
whether TLR4 stimulation influenced PrPc expression.  Prnp mRNA levels in WT mice were 1584 
monitored by qRT-PCR from 2-48 hpi after TLR4 stimulation in 2 and 21 day old mice (Fig 4.1B).  1585 
No significant differences in brain PrPc mRNA levels were observed in response to TLR 4 1586 
stimulation in mice of either age over the time course examined. 1587 
 1588 
Tlr4 and Tlr9 gene expression is not affected by a lack of PrPc under homeostatic or 1589 
inflammatory conditions 1590 
We next tested whether PrPc influences Tlr mRNA expression.  Basal mRNA levels of Tlrs 1591 
3, 4, 7, 8 and 9 were examined in the brain, spleen and thymus of WT and PrP-/- mice at 2, 14 1592 
and 42 d.o. (Fig 4.2 A-C).  Over the time period examined, mRNA levels of Tlrs 3, 4, 7 and 9 rose 1593 
four- to six-fold in the brains of both WT and PrP-/- mice, while Tlr8 levels remained unchanged.  1594 
Splenic Tlr levels increased two- to five-fold in WT and PrP-/- mice while thymic Tlr levels were 1595 
unchanged with age.  Lack of PrPc did not significantly influence basal Tlr expression in any 1596 
tissue or time point examined.  The effect of PrP-/- on Tlr4 and 9 mRNA levels after TLR 1597 
stimulation was also examined (Fig 4.2 D & E).  We saw no significant differences in brain Tlr4 or 1598 
Tlr9 mRNA levels between WT and PrP-/- mice of either age in response to LPS or CpG, nor were 1599 
agonist-specific alterations in Tlr4 or Tlr9 levels were detected.  1600 
 1601 
Lack of effect of PrPc expression on cytokine responses to intracerebral TLR4 or TLR9 1602 
stimulation 1603 
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To determine whether PrPc influences cytokine responses, we treated mice with LPS or 1604 
CpG by IC inoculation.  As controls, mice were either left uninoculated or inoculated with PBS.  1605 
Cytokine and growth factor protein levels in whole brain homogenates were examined by 1606 
multiplex bead assay at 12 hpi in WT and PrP-/- neonatal (Fig 4.3) and weanling (Fig 4.4) brain 1607 
tissue.  Although strong inflammatory cytokine induction was observed, no differences in 1608 
production of the inflammatory cytokines IL-1b, IL-6, IL-12, Cxcl1, Cxcl9, Ccl2 or Ccl3 were 1609 
detected between WT and PrP-/- brain tissue in 2 or 21 d.o. mice.  Additionally, no PrPc-1610 
dependent differences were noted for the anti-inflammatory cytokine IL-10.  Similar results 1611 
were observed for the cytokines IL-1a, IL-2, IL-5 and TNF and the growth factors FGF and VEGF 1612 
(data not shown).  IL-4, IL-13, IL-17, IFNγ and GM-CSF were also assayed but were not present 1613 
at detectable levels under the conditions tested.  1614 
Due to limited quantities of mice available in the Tg7 strain, we only examined the 1615 
cytokine responses to IC PBS or CpG in weanling mice of this strain. Figure 4.5 shows production 1616 
of IL-1b, IL-12, CCL3, CXCL9 and CXCL10 in Tg7, WT and PrP-/- brains and is representative of the 1617 
cytokine responses observed in weanling Tg7 mice.  PrPc overexpression in Tg7 mice did not 1618 
influence cytokine production in the brain. 1619 
In previous studies using the IRW mouse strain, some cytokine levels in the brain 1620 
remained heightened at 48 and 96 hpi after TLR stimulation (Butchi et al., 2008).  Therefore, we 1621 
also examined neonatal brain homogenates at 48 and 96 hpi to determine whether PrPc 1622 
influenced late cytokine responses.  However, all cytokines had returned to basal levels in 1623 
C57Bl/10 WT and PrP-/- mice by 48 hpi (data not shown). 1624 
 1625 
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PrPc expression did not influence glial activation  1626 
To test for effects of PrPc on other aspects of glial activation, we assessed induction of 1627 
glial activation markers by qRT-PCR in neonatal WT and PrP-/- brains (Fig 4.6).  We examined 1628 
mRNA expression of glial activation markers at 6 and 12 hpi after TLR4 or TLR9 stimulation.  1629 
However, most mRNAs had returned to basal levels by 12 hpi, so only the 6 hour data are 1630 
shown here.  Cd80 is expressed by activated microglia while Nos2, Gpr84 and Icam1 are 1631 
induced in both microglia and astrocytes in response to neuroinflammation.  No significant 1632 
differences were detected between WT and PrP-/- brains in the mRNA levels of any of the glial 1633 
activation markers tested.   1634 
We also performed histologic analyses of WT and PrP-/- brain sections that were taken at 1635 
12, 48 and 96 after inoculation with PBS, LPS, CpG, as well as uninoculated controls.  Tissues 1636 
were stained with hematoxylin and eosin, glial fibrillary acidic protein (GFAP), or ionized 1637 
calcium binding adaptor molecule 1 (IBA1). No significant differences in inflammation, 1638 
peripheral immune cell infiltration, astrocytic activation or microglial activation were observed 1639 
(data not shown).   1640 
 1641 
Discussion 1642 
Microglia and astrocytes are the primary immune-responsive cells of the brain and have 1643 
many overlapping functions, including release of inflammatory and neurotrophic factors and 1644 
phagocytosis of debris.  Prion protein has been demonstrated to influence microglial activation 1645 
in vitro (Brown et al., 1996; Brown et al., 1998; Herms et al., 1997).  Astrocytic PrPc plays a role 1646 
in both astrocytic and neuronal development (Arantes et al., 2009; Lima et al., 2007).  PrPc has 1647 
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not yet been shown to influence the immune-specific functions of astrocytes.  We hypothesized 1648 
that PrPc expression would influence the neuroimmune response in vivo.  However, after 1649 
measuring several parameters of the neuroinflammatory response, we have not observed any 1650 
differences between WT, PrP-/- and PrPc overexpressing mice.   1651 
The apparent discord between our results and published studies may be because our 1652 
experiments utilized in vivo models while most published studies were restricted to in vitro 1653 
models.  Discrepancies between in vitro and in vivo responses were recently noted by Mariante 1654 
et al., who observed that TNF up-regulates neutrophil expression of PrPc in vitro but not in vivo 1655 
(Mariante et al., 2012).  This group also noted that neutrophil, but not brain, PrPc was up-1656 
regulated in response to LPS.  Another possibility is that PrPc influences the inflammatory 1657 
response of a specific cell type in wild-type mice but in a manner that is undetectable in PrP-/- 1658 
mice due to compensation by another molecule or cell type.   1659 
It is possible that purified TLR agonist is not sufficient to stimulate PrPc-dependent 1660 
differences in the neuroinflammatory response.  TLR 4 and 9 agonists were chosen because 1661 
interactions between PrPc and nucleic acids are well-documented and PrPc has recently also 1662 
been shown to bind LPS.  However, upon intracranial inoculation of mice with ECM virus, Nasu-1663 
Nishimura et al. reported that PrP-/- mice displayed reduced recruitment of peripheral immune 1664 
cells into the brain and reduced microglial activation when compared with WT cells (Nasu-1665 
Nishimura et al., 2008).  Since ECM virus infection activates a broader range of immune pattern 1666 
recognition receptors, it is conceivable that PrPc-dependent modulation of the immune system 1667 
occurs through a mechanism independent of TLR signaling.   1668 
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The above PrPc-associated differences were only apparent when using 15 week old mice 1669 
but not in experiments with 6 week old mice (Nasu-Nishimura et al., 2008).  Similarly, Keshet et 1670 
al. found that age influences the activity and subcellular localization of neuronal nitric oxide 1671 
synthase (nNOS) (Keshet et al., 1999).  In 30 day old mice, PrP knock out did not impair nNOS 1672 
function or localization to lipid rafts.  Both localization and enzymatic activity were impaired in 1673 
100 day old PrP-/- brains.  These results imply that either PrPc influences the neuroinflammatory 1674 
response only in mature mice, or compensatory mechanisms for mitigating the loss of PrPc 1675 
decline with age.  We did not examine the PrPc-dependent response in mature mice.  It is 1676 
possible that PrPc could influence the TLR response in older mice. 1677 
The cellular differentiation state of astrocytes and microglia may influence the function 1678 
of PrPc within these cell types.  Although PrPc is expressed in astrocytes and microglia in young 1679 
mice, it does not appear to influence the inflammatory response in these cells.  PrPc is involved 1680 
in development of the central nervous system.  Conceivably, PrPc in young glial cells could be 1681 
restricted to developmental functions but in older glial cells takes on immunoregulatory 1682 
functions.   1683 
PrPc and TLR4 share several physiological characteristics.  Both PrPc and TLR4 are plasma 1684 
membrane proteins that migrate into lipid rafts upon ligand binding, which stimulates 1685 
endocytosis (Husebye et al., 2006; Lee et al., 2007; Marella et al., 2002; Triantafilou et al., 1686 
2004).  In addition to binding PAMPs, TLRs bind damage-associated molecular patterns 1687 
(DAMPs), which can elicit an inflammatory response in the absence of infection.  Both TLR4 and 1688 
PrPc interact with the DAMPs heparan sulfate and hyaluronan (Johnson et al., 2002; Pan et al., 1689 
2002; Termeer et al., 2002).  It is unclear which accessory proteins mediate the transfer of 1690 
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DAMPs to TLR4.  Although we have not found PrPc to influence the inflammatory response to 1691 
TLR signaling in response to PAMPs, it is intriguing to consider whether PrPc could be an 1692 
accessory protein in TLR4 DAMP signaling. 1693 
PrPc appears to be developmentally regulated in the brain and plays a role in many 1694 
developmental functions.  Additionally, PrPc has been shown to influence immune cell function, 1695 
primarily in the periphery.  We hypothesized that PrPc would influence the neuroinflammatory 1696 
response in young mice, perhaps by acting as a scavenger receptor for TLR ligands.  However, in 1697 
our investigation of the inflammatory response to IC TLR 4 or 9 stimulation, we did not observe 1698 
PrPc –dependent differences in the acute neuroinflammatory response, as measured by 1699 
cytokine production and glial activation.  1700 
 1701 
 1702 
 1703 
 1704 
 1705 
 1706 
 1707 
 1708 
 1709 
 1710 
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 1711 
Figure 4.1 Brain PrPc expression is influenced by age but not TLR4 or TLR9 stimulation.  (A) 1712 
Prion protein (Prnp) transcript levels were measured in the brain, spleen and thymus of 1713 
C57Bl/10 WT untreated mice at 2, 14 and 42 days old.  Only brain tissue showed an age-1714 
dependent increase in Prnp expression. Housekeeping gene expression was averaged using 1715 
Gusb, Actb and Rpl32.  n=4-5 per group.  (B) Prnp mRNA levels in WT neonatal and weanling 1716 
brains were analyzed from 2 to 48 hpi after inoculation with either PBS or LPS.  No differences 1717 
in Prnp levels were observed. Data are presented as mean +/- SE.  n=5-6 per group.  1718 
 1719 
 1720 
 1721 
 1722 
 1723 
 1724 
 1725 
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 1726 
Figure 4.2 Tlr mRNA expression is influenced by age but not PrPc expression. Tlr transcript 1727 
levels were measured in the brain (A), spleen (B) and thymus (C) of WT and PrP-/- untreated 1728 
mice at 2, 14 and 42 days old.  mRNA expression levels of Tlrs 3, 4, 7 and 9 increased steadily 1729 
with age in the brain and spleen.  A similar trend was observed in the thymus for Tlr4 and Tlr7 1730 
expression.  No differences in basal Tlr mRNA levels were observed between WT and PrP-/- 1731 
tissues. Housekeeping gene expression was averaged using Gusb, Actb and Rpl32.  Data are 1732 
presented as mean +/- SE.  (D & E) At 12 hpi after TLR4 or 9 stimulation, Tlr4 and Tlr9 mRNA 1733 
levels in WT and PrP-/- brains were examined.  No significant PrPc-dependent differences were 1734 
noted in neonatal (D) or weanling (E) mice. Data are presented as mean +/- SD.  n=3-5 per 1735 
group. 1736 
 1737 
~ 83 ~ 
 
 1738 
Figure 4.3 PrPc expression does not alter cytokine responses to TLR 4 or 9 stimulation in 1739 
neonatal brains.  WT and PrP-/- mice were inoculated with PBS, LPS or CpG intracerebrally (IC).  1740 
Uninoculated controls were used as an additional control group.  Cytokine protein levels at 12 1741 
hpi were measured in neonatal brain tissue by multiplex.  Representative cytokines are shown 1742 
here.  WT data was previously shown in Figures 3.1 and 3.2.  No significant differences in 1743 
cytokine production were observed between WT and PrP-/- brains. Data are presented as mean 1744 
+/- SD.  # indicates treatment group contains samples above the dynamic range (based on 1745 
standard curve).  Outliers detected by Grubbs’ test were excluded.  Statistical analysis was 1746 
completed by two-way analysis of variance with Sidak’s multiple comparisons test.  For both 1747 
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WT and PrP-/- mice, data contain the combined results of two independent experiments.  n=10-1748 
13 per group. 1749 
 1750 
 1751 
 1752 
 1753 
 1754 
 1755 
 1756 
 1757 
 1758 
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 1759 
Figure 4.4 PrPc expression does not alter cytokine responses to TLR 4 or 9 stimulation in 1760 
weanling brains.  WT and PrP-/- mice were inoculated with PBS, LPS or CpG intracerebrally (IC).  1761 
Uninoculated controls were used as an additional control group.  Cytokine protein levels at 12 1762 
hpi were measured in weanling brain tissue by multiplex.  Representative cytokines are shown 1763 
here.  WT data was previously shown in Figures 3.1 and 3.2.  No significant differences in 1764 
cytokine production were observed between WT and PrP-/- tissue.  Data are presented as mean 1765 
+/- SD.  Outliers detected by Grubbs’ test were excluded.  Statistical analysis was completed by 1766 
two-way analysis of variance with Sidak’s multiple comparisons test.  n=5-6 per group. 1767 
 1768 
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 1769 
Figure 4.5 PrPc overexpression does not influence cytokine responses to TLR9 stimulation in 1770 
weanling brains.  Cytokine responses in Tg7 PrPc overexpressing mice were compared to 1771 
responses in WT and PrP-/- weanling mice.  WT and PrP-/- data are also shown in Figure 4.5.  1772 
Brain cytokine levels were measured at 12 hpi by multiplex.  Representative data are shown 1773 
here.  No significant differences in cytokine levels were detected between WT, PrP-/- and Tg7 1774 
mice.   Data are presented as mean +/- SD.  Outliers detected by Grubbs’ test were excluded.  1775 
Statistical analysis was completed by two-way analysis of variance with Sidak’s multiple 1776 
comparisons test.  n=5-6 per group. 1777 
 1778 
 1779 
 1780 
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 1782 
Figure 4.6 PrP expression does not alter expression of glial activation markers in response to 1783 
LPS or CpG.  Expression of astrocytic and microglial activation markers was examined in WT and 1784 
PrP-/- brains at 6 hours after TLR stimulation.  Since a two-fold change is the smallest change 1785 
that can be observed by qRT-PCR, differences in mRNA expression that were less than two-fold 1786 
were not considered significant.  No significant differences in expression of the glial activation 1787 
markers Nos2, Cd80, Icam1 and Gpr84 were observed between WT and PrP-/- brains.  n=5-7 per 1788 
group.  1789 
 1790 
 1791 
 1792 
 1793 
 1794 
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CHAPTER FIVE 1795 
EXPERIMENTAL METHODS 1796 
 1797 
Ethics statement  1798 
All animal research was carried out in adherence with protocols approved by the 1799 
National Institutes of Health Rocky Mountain Laboratories Animal Care and Use Committee. 1800 
 1801 
Animal models and inoculation of TLR agonists 1802 
All mice were housed and maintained by the Rocky Mountain Laboratories Veterinary 1803 
Branch (Hamilton, MT).  Mice were maintained under pathogen-free conditions with regular 1804 
light/dark cycles and given food and water ad libitum.  WT C57Bl/10 and PrP-/- C57Bl/10 mice 1805 
were inoculated at 36-48 hours of age.  Newborn mice were anaesthetized by hypothermia 1806 
prior to intracerebral (IC) inoculations using a Hamilton syringe with a 33-gauge needle.  Three 1807 
week old mice were anaesthetized by isofluorane inhalation prior to inoculation.  Mice were 1808 
inoculated once in each hemisphere with a solution volume of 3 µl per hemisphere.  Mice were 1809 
inoculated with one of two TLR agonists, lipopolysaccharide (LPS) or unmethylated CpG-rich 1810 
oligonucleotides (CpG), or with a phosphate-buffered saline (PBS) control.  Mice were weighed 1811 
and amount of TLR agonist used was based on average weight at each age.  For TLR stimulation, 1812 
mice were inoculated with either 0.5 µg LPS per gram of body weight or 0.125 µg CpG per gram 1813 
of body weight.  For neonatal mice, this meant a total inoculum of 1 µg LPS or 0.25 µg (40 1814 
picomoles) CpG.  For three week old mice, this translated to 3.8 µg LPS or 0.95 µg CpG.  As an 1815 
~ 89 ~ 
 
additional control, another group of mice remained completely uninoculated.  All experimental 1816 
and control groups contained mice from multiple litters that were inoculated on different days.   1817 
 1818 
Harvesting of tissues for mRNA and protein analysis 1819 
Prior to harvesting of tissues, all animals were anaesthetized by inhalation of 1820 
isofluorane, followed by axillary incision and cervical dislocation at the specified time point.  1821 
Brains were snap frozen in liquid nitrogen and stored at -80˚C. 1822 
 1823 
TLR agonists 1824 
TLR4 agonist ultra pure LPS (Cat. No. tlrl-3pelps) and TLR9 agonist phosphorothioated 1825 
CpG type B *5’-tcc atg acg ttc ctg acg tt-3’+ (Cat. No. tlrl-1826) were purchased from InvivoGen.  1826 
Agonist stocks were suspended in endotoxin-free water, aliquoted and stored at -20˚C.  1827 
Immediately prior to use, agonists were diluted in endotoxin-free, PBS-buffered solution.   1828 
 1829 
Protein quantification 1830 
For protein quantification, brains were weighed and homogenized in Bio-Plex cell lysis 1831 
buffer (Bio-Rad Cat. No. 171-304012) containing PMSF (Sigma Cat. No. P-7626) and Complete 1832 
Mini Protease Inhibitor Cocktail (Roche Cat. No. 11836153001).  Brains in cell lysis buffer were 1833 
homogenized using Kontes pellet pestles (Fisher Scientific) and diluted to a final concentration 1834 
of 300 mg/ml wet weight.  Samples were centrifuged at 4,500 × g for 15 minutes at 4˚C and 1835 
supernatants collected for further analysis.  Cytokine and chemokine protein levels in brain 1836 
homogenate supernatants were analyzed using the Invitrogen Mouse Cytokine Twenty-Plex 1837 
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Antibody Bead kit (Cat. No. LMC006) on a Bio-Rad Bio-Plex 200 system.  Individual protein 1838 
concentrations were calculated using standard curves generated from standards provided with 1839 
the Twenty-Plex kit.  IL-6 (Cat. No. M6000B) and CCL2 (Cat. No. MJE00) protein levels were also 1840 
analyzed using R & D Systems ELISA kits. Individual protein concentrations were calculated 1841 
using standard curves generated from standards provided with the ELISA kits. 1842 
 1843 
Quantification of mRNA Expression by Real-Time PCR 1844 
Total RNA was extracted using the Qiagen RNeasy Mini Kit (Cat. No. 74106) per 1845 
manufacturer’s instructions.  RNA was then treated with DNase (Ambion Cat. No. AM2224) for 1846 
30 min at 37˚C, followed by a final purification and concentration using the Zymo Research RNA 1847 
Clean-up kit (Cat. No. R1018).  Complimentary DNA (cDNA) was generated from the isolated 1848 
RNA using the iScript cDNA Synthesis kit (Bio-Rad Cat. No. 170-8891).  All primers were 1849 
designed using Primer3 and were gene-specific in blast searches performed using the National 1850 
Center for Biotechnology Information database.  Real-time PCR was performed using iTAQ SYBR 1851 
Green Supermix with ROX (Bio-Rad Cat. No. 1725852) on an Applied Biosystems PRISM 7900HT 1852 
instrument.  All samples were run in triplicate.  The baseline was automatically set and the CT 1853 
was manually set to intersect the mid-log phase of PCR curves at 0.19.  Dissociation curves were 1854 
used to verify that only a single gene product was amplified in each sample.  RNA that was not 1855 
reverse transcribed and water were used as negative controls.   Primers used are listed in Table 1856 
6.1. 1857 
 1858 
 1859 
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Preparation of brain tissue for flow cytometry 1860 
 Animals were anaesthetized by inhalation of isofluorane, followed by perfusion through 1861 
the left ventricle of the heart with ice cold 1x Hank’s balanced salt solution (HBSS) without  1862 
calcium and magnesium (Gibco Cat. No. 14185).  Whole brains were removed and sliced into 1863 
several pieces using a razor.  Weanling brain homogenates were then Dounce homogenized 1864 
while neonatal brain homogenates were triturated using a 5 ml pipet.  Neonatal and weanling 1865 
brain homogenates were further triturated using a 20G needle.  For samples that were 1866 
enzymatically digested, brain homogenates were incubated in 0.05% Collagenase D (Roche Cat. 1867 
No. 11 088 882 001), 0.09 U/ml Dispase I (Sigma Cat. No. D4818) and 0.025 U/ml DNase I 1868 
(Sigma Cat. No. D4527) in 1x HBSS at room temperature for 30 minutes with continuous 1869 
rocking.  Neonatal tissue was digested in 5 mls per brain, 10 mls per brain was used for 1870 
weanling tissue.  Vigorous pipetting was used to dislodge any cells that may have adhered to 1871 
the sides of tubes during enzymatic digestion.  Cell suspensions were then placed on 0/30/70% 1872 
Percoll gradients.  Percoll (Sigma Cat. No. P4937) was diluted to the appropriate concentration 1873 
using HBSS.  One Percoll gradient was used per neonatal brain and two Percoll gradients per 1874 
weanling brain.  After centrifugation for 20 minutes at 4° C, the fraction at the 30/70% interface 1875 
was removed for further analysis of CNS immune cells.  For samples that were prepared using 1876 
myelin depletion columns, brain homogenates were pre-incubated with myelin removal beads 1877 
(Miltenyi Biotec Cat. No. 130-094-544) following manufacturer’s instructions.  One neonatal 1878 
brain homogenate was placed on an LS column (Miltenyi Biotec Cat. No. 130-042-401) while 1879 
two LD columns (Miltenyi Biotec Cat. No. 130-042-901) were used per weanling brain 1880 
homogenate.   1881 
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 1882 
Flow cytometric analysis of CNS populations ex vivo 1883 
  After generation of single cell suspensions using either enzymatic digestion and Percoll 1884 
gradients, or myelin depletion columns, cells were then counted by hemocytometer.  Aqua 1885 
Live/Dead staining (Life Technologies Cat. No. L34657) was performed at this time on some 1886 
samples.  During development of the flow cytometry protocol, as described in Chapter 4, 1887 
samples of the same age and treatment group were pooled.  For flow cytometry experiments 1888 
described in Chapter 2, samples were not pooled, permitting the analysis of biological 1889 
replicates.  Neonatal and weanling samples that were compared to one another were examined 1890 
in the same experiment, as were PBS- and LPS-treated samples.  Samples were plated onto 96-1891 
well plates. Similar numbers of cells were added to each well.  Cells were fixed in 2% 1892 
paraformaldehyde, then permeabilized in 0.1% saponin/2% bovine serum albumin (BSA)/1x 1893 
PBS.  Samples were incubated in an FC blocking solution containing rat anti-mouse CD16/CD32 1894 
Fcγ III/II antibody (BD Pharmingen Cat. No. 553142) in 2% donkey serum/0.1% saponin/2% 1895 
BSA/1x PBS.  Cells were incubated with fluorescently-conjugated antibodies at room 1896 
temperature.  After washing twice, cells were resuspended in PBS and analyzed on a FACSAria 1897 
flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences).  Data were analyzed 1898 
using FCS Express.  A list of antibodies used is given in Table 6.2. 1899 
 1900 
Harvesting and preparation of spleen tissue for flow cytometry 1901 
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Spleens were Dounce homogenized, then incubated in Ammonium-Chloride-Potassium 1902 
(ACK) buffer to lyse red blood cells.  Samples were then centrifuged, resuspended in PBS, and 1903 
single cell suspensions were prepared for flow cytometry as described for brain cells (above). 1904 
 1905 
 1906 
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 1908 
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 1920 
 1921 
 1922 
 1923 
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Table 6.1 Primers used for qRT-PCR 1924 
Gene name Forward primer Reverse primer 
Actb CAGCTTCTTTGCAGCTCCTT CACGATGGAGGGGAATACAG 
Rpl32 ACATCGGTTATGGGAGCAAC CACCTCCAGCTCCTTGACAT 
Gapdh AACGACCCCTTCATTGAC TCCACGACATACTCAGCA 
Gusb CAATGAGCCTTCCTCTGCTC CTGCATCATATTTGGCGTTG 
Cd3e GAGCACCCTGCTACTCCTTG TGAGCAGCCTGATTCTTTCA 
Cd80 CCTTGCCGTTACAACTCTCC CAGGCCCAGGATGATAAGAG 
Cd8a TCAGTTCTGTCGTGCCAGTC GCCGACAATCTTCTGGTCTC 
Ela2 CTTCGAGAATGGCTTTGACC ACGTTGGCGTTAATGGTAGC 
F4/80 ACAAGTGTCTCCCTCGTGCT AACAT GTGCTTTCCACAGTC 
Gfap CGTTTCTCCTTGTCTCGAATGAC TCGCCCGTGTCTCCTTGA 
Gpr84 CTGACTGCCCCTCAAAAGAC GGAGAAGTTGGCATCTGAGC 
Icam1 AGGGCTGGCATTGTTCTCTA CTTCAGAGGCAGGAAACAGG 
Ifnb1 AGCACTGGGTGGAATGAGAC TCCCACGTCAATCTTTCCTC 
IL-6 CCGGAGAGGAGACTTCACAG TCCACGATTTCCCAGAGAAC 
Cxcl10 CAGTGAGAATGAGGGCCATAGG CTCAACACGTGGGCAGGAT 
Itgax ATGTTGGAGGAAGCAAATGG TGGGGCTGACTTAGAGGAGA 
Ccl2 CCCACTCACCTGCTACT TCTGGACCCATTCCTTCTTG 
Ccl3 ACCATGACACTCTGCAACCA GATGAATTGGCGTGGAATCT 
Nos2 GACGGATAGGCAGAGATTGG CACATGCAAGGAAGGGAACT 
Prnp GGACCGCTACTACCGTGAAA TCATCTTCACATCGGTCTCG 
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Slamf7 GCAGAACTCAGCAATGTCCA GAAAGCCCAACCTCGATACA 
Tlr3 AGCTTTGCTGGGAACTTTCA ATCGAGCTGGGTGAGATTTG 
Tlr4 GGCAGCAGGTGGAATTGTAT AGGATTCGAGGCTTTTCCAT 
Tlr7 GGCATTCCCACTAACACCAC TTGGACCCCAGTAGAACAGG 
Tlr8 TCGTCTTGACCATTTGTGGA AATGCTCCATTTGGGATTTG 
Tlr9 ACTTCGTCCACCTGTCCAAC TCATGTGGCAAGAGAAGTGC 
Tnf CCACCACGCTCTTCTGTCTAC GAGGGTCTGGGCCATAGAA 
 1925 
 1926 
 1927 
 1928 
 1929 
 1930 
 1931 
 1932 
 1933 
 1934 
 1935 
 1936 
 1937 
 1938 
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Table 6.2 Antibodies used for flow cytometry 1940 
Antigen Clone Vendor Cat. No. 
CD11a-eFluor450 M17/4 eBiosciences 48-0111 
CD11b-AF700 M1/70 eBiosciences 56-0112-82 
CD11b-V500 M1/70 BD Horizon 562127 
CD172a-FITC P84 BD Pharmingen 560316 
CD200R-PerCP-
eFluor710 
OX110 eBiosciences 46-5201 
CD45-PE 30-F11 BD Pharmingen 553081 
CD86-AF700 GL1 BD Pharmingen 560581 
F4/80-APC BM8 eBiosciences 17-4801-82 
GFAP-AF488 -- Cell Signaling 3655 
LY6C-AF700 AL-21 BD Pharmingen 561237 
SLAMF7-Fluorescein -- R&D Systems FAB4628F 
 1941 
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CHAPTER SIX 1950 
CONCLUDING REMARKS 1951 
In humans, gestational infections have been linked to later neurological illness in 1952 
offspring.  The correlation between infection and neurological illness has been most often 1953 
made for schizophrenia, a disease that usually does not manifest itself until late adolescence or 1954 
early adulthood.  While such complex neurological diseases cannot be fully reproduced in 1955 
animal models, specific pathological symptoms can.  For example, in animal models of 1956 
schizophrenia, perinatal immune stimulation can replicate specific behavioral and cognitive 1957 
disabilities, including the delayed onset.     1958 
The underlying mechanisms that may connect early infection with later neurological 1959 
illness are unknown.  In humans, a variety of infectious agents, including viruses, bacteria and 1960 
parasites have been associated with neurological illness.  In animal models, inoculation with 1961 
infectious agents, TLR ligands or the cytokine IL-6 can lead to neurodevelopmental 1962 
abnormalities.  Collectively, this suggests it is a generalized response to infection that may 1963 
increase one’s risk of neurological illness.  In this respect, the developing immune response in 1964 
the brain is of particular interest.  1965 
To better understand how the neonatal immune response differs from other ages, it is 1966 
helpful to directly compare the response of neonatal immune cells with those from older 1967 
animals that are known to have a more mature immune system.  Since weanling mice are less 1968 
susceptible to neurological infection than neonatal mice, we compared the neonatal cytokine 1969 
response to IC TLR4 or TLR9 stimulation with that of weanling mice.   1970 
 1971 
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In our comparisons of the cytokine response at each age, we found that production of 1972 
many cytokines was increased in neonatal brains.  This included pro-inflammatory cytokines 1973 
that are elevated in a variety of neurological conditions, such as IL-1b, TNF and IL-6, as well as 1974 
cytokines whose roles in neuroimmunity are not well characterized, such as IL-5.  While some of 1975 
these cytokines, such as IL-6, have previously been linked to neurodevelopmental illness in 1976 
animal models of disease, others, such as IL-5, have not.  Knowledge of cytokines that are 1977 
elevated during the neonatal neuroinflammatory response may lead to important insights into 1978 
their impact on neurodevelopment.  The neonatal cytokine response we observed in the brain 1979 
differed from what has been reported in some other tissues after TLR stimulation, including the 1980 
ability to produce large amounts of strongly pro-inflammatory cytokines such as IL-1b and TNF.  1981 
In future studies, it will be interesting to directly compare the production of these cytokines in 1982 
the brains and peripheral tissues of neonates.  It is somewhat surprising that their expression 1983 
would be inhibited to a greater extent in peripheral tissues, than in the brain, where there is a 1984 
greater risk of long-term damage. 1985 
Microglia and astrocytes are important immune- and TLR-responsive cells in the brain 1986 
parenchyma.  In addition, macrophages inhabit the perivascular spaces surrounding brain 1987 
tissue.  We sought to characterize the expression of activating and inhibitory receptors on these 1988 
cells at each age.  Although we came up against several unexpected obstacles in our attempts 1989 
to characterize CNS immune-responsive populations ex vivo using flow cytometry, we did 1990 
observe age-specific differences in expression of activating 2-integrins and inhibitory CD172a 1991 
on microglia.  Rather unexpectedly, considering the more amoeboid phenotype of neonatal 1992 
microglia, neonatal microglia did not express increased amounts of all activating proteins 1993 
~ 99 ~ 
 
examined, nor did they express lower levels of some of the inhibitory proteins examined, when 1994 
compared with weanling microglia.  In future studies, it would be interesting to directly 1995 
compare regulation of microglial activation at each age, as our data could suggest some age-1996 
dependent differences in microglial regulation.   1997 
We also noted relatively high expression of SLAMF7 on neonatal microglia.  Since many 1998 
immunoregulatory proteins are expressed at lower levels on microglia than on other immune 1999 
cell populations, it will be particularly interesting to examine how SLAMF7 influences neonatal 2000 
microglial activation, as it may be particularly important for their function.  Since microglial 2001 
SLAMF7 has not been previously described, and SLAMF7 can have both activating and inhibitory 2002 
functions, its role in microglial physiology is not immediately clear.    2003 
In addition, we observed age-specific differences in the ratios of different CD45hi 2004 
populations in the brain, which could have important consequences for the immune response 2005 
under a variety of conditions at each age. 2006 
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